<?xml version="1.0" encoding="UTF-8" standalone="no"?>

<MINiML
   xmlns="http://www.ncbi.nlm.nih.gov/geo/info/MINiML"
   xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
   xsi:schemaLocation="http://www.ncbi.nlm.nih.gov/geo/info/MINiML http://www.ncbi.nlm.nih.gov/geo/info/MINiML.xsd"
   version="0.5.0" >

  <Contributor iid="contrib1">
    <Person><First>Sun Hee</First><Last>Ahn</Last></Person>
    <Laboratory>Infectious Diseases (Staphylococcal Disease)</Laboratory>
    <Department>Medicine</Department>
    <Organization>Duke University</Organization>
    <Address>
      <Line>Stead Bldg, RM 1546A </Line>
      <City>Durham</City>
      <State>NC</State>
      <Zip-Code>27710</Zip-Code>
      <Country>USA</Country>
    </Address>
  </Contributor>

  <Contributor iid="contrib2">
    <Organization></Organization>
    <Email>geo@ncbi.nlm.nih.gov, support@affymetrix.com</Email>
    <Phone>888-362-2447</Phone>
    <Organization>Affymetrix, Inc.</Organization>
    <Address>
      <City>Santa Clara</City>
      <State>CA</State>
      <Zip-Code>95051</Zip-Code>
      <Country>USA</Country>
    </Address>
    <Web-Link>http://www.affymetrix.com/index.affx</Web-Link>
  </Contributor>

  <Contributor iid="contrib3">
    <Person><First>Sun</First><Middle>H</Middle><Last>Ahn</Last></Person>
  </Contributor>

  <Contributor iid="contrib4">
    <Person><First>Ephraim</First><Middle>L</Middle><Last>Tsalik</Last></Person>
  </Contributor>

  <Contributor iid="contrib5">
    <Person><First>Derek</First><Last>Cyr</Last></Person>
  </Contributor>

  <Contributor iid="contrib6">
    <Person><First>Yurong</First><Last>Zhang</Last></Person>
  </Contributor>

  <Contributor iid="contrib7">
    <Person><First>Raymond</First><Middle>J</Middle><Last>Langley</Last></Person>
  </Contributor>

  <Contributor iid="contrib8">
    <Person><First>Jennifer</First><Middle>C</Middle><Last>van Velkinburgh</Last></Person>
  </Contributor>

  <Contributor iid="contrib9">
    <Person><First>Seth</First><Middle>W</Middle><Last>Glickman</Last></Person>
  </Contributor>

  <Contributor iid="contrib10">
    <Person><First>Charles</First><Middle>B</Middle><Last>Cairns</Last></Person>
  </Contributor>

  <Contributor iid="contrib11">
    <Person><First>Aimee</First><Middle>K</Middle><Last>Zaas</Last></Person>
  </Contributor>

  <Contributor iid="contrib12">
    <Person><First>Emanuel</First><Middle>P</Middle><Last>Rivers</Last></Person>
  </Contributor>

  <Contributor iid="contrib13">
    <Person><First>Ronny</First><Middle>M</Middle><Last>Otero</Last></Person>
  </Contributor>

  <Contributor iid="contrib14">
    <Person><First>Stephen</First><Middle>F</Middle><Last>Kingsmore</Last></Person>
  </Contributor>

  <Contributor iid="contrib15">
    <Person><First>Joseph</First><Last>Lucas</Last></Person>
  </Contributor>

  <Contributor iid="contrib16">
    <Person><First>Christopher</First><Middle>W</Middle><Last>Woods</Last></Person>
  </Contributor>

  <Contributor iid="contrib17">
    <Person><First>Tim</First><Last>Veldman</Last></Person>
  </Contributor>

  <Contributor iid="contrib18">
    <Person><First>Geoffrey</First><Middle>S</Middle><Last>Ginsburg</Last></Person>
  </Contributor>

  <Contributor iid="contrib19">
    <Person><First>Vance</First><Middle>G</Middle><Last>Fowler</Last></Person>
  </Contributor>

  <Database iid="GEO">
    <Name>Gene Expression Omnibus (GEO)</Name>
    <Public-ID>GEO</Public-ID>
    <Organization>NCBI NLM NIH</Organization>
    <Web-Link>http://www.ncbi.nlm.nih.gov/geo</Web-Link>
    <Email>geo@ncbi.nlm.nih.gov</Email>
  </Database>

  <Platform iid="GPL571">
    <Status database="GEO">
      <Submission-Date>2003-11-07</Submission-Date>
      <Release-Date>2003-11-07</Release-Date>
      <Last-Update-Date>2018-12-06</Last-Update-Date>
    </Status>
    <Title>[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array</Title>
    <Accession database="GEO">GPL571</Accession>
    <Technology>in situ oligonucleotide</Technology>
    <Distribution>commercial</Distribution>
    <Organism taxid="9606">Homo sapiens</Organism>
    <Manufacturer>Affymetrix</Manufacturer>
    <Manufacture-Protocol>
see manufacturer's web site

The GeneChip Human Genome U133A 2.0 Array is a single array representing 14,500 well-characterized human genes that can be used to explore human biology and disease processes.
Provides coverage of well-substantiated genes in the transcribed human genome on a single array
Analyzes the expression level of 18,400 transcripts and variants, including 14,500 well-characterized human genes
Comprised of more than 22,000 probe sets and 500,000 distinct oligonucleotide features
All probe sets represented on the GeneChip Human Genome U133A Array are identically replicated on the GeneChip Human Genome U133A 2.0 Array
Sequences used in the design of the array were selected from GenBank®, dbEST, and RefSeq. The sequence clusters were created from the UniGene database (Build 133, April 20, 2001) and then were refined by analysis and comparison with a number of other publicly available databases including the Washington University EST trace repository and the University of California, Santa Cruz Golden-Path human genome database (April 2001 release).

    </Manufacture-Protocol>
    <Description>
Affymetrix submissions are typically submitted to GEO using the GEOarchive method described at http://www.ncbi.nlm.nih.gov/projects/geo/info/geo_affy.html

June 03, 2009: annotation table updated with netaffx build 28
June 08, 2012: annotation table updated with netaffx build 32
July 01, 2016: annotation table updated with netaffx build 35
    </Description>
    <Web-Link>http://www.affymetrix.com/support/technical/byproduct.affx?product=hgu133-20</Web-Link>
    <Web-Link>http://www.affymetrix.com/analysis/index.affx</Web-Link>
    <Relation type="Alternative to" target="GPL5356" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL5705" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL7763" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL8414" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL9188" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL13447" comment="Alternative CDF [Ensembl v58, Hs133Av2_Hs_ENSG]" />
    <Relation type="Alternative to" target="GPL14604" comment="Alternative CDF [Brainarray Version 10, Hs133Av2_Hs_ENTREZG]" />
    <Relation type="Alternative to" target="GPL17486" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL18033" comment="alternative" />
    <Relation type="Alternative to" target="GPL18034" comment="alternative" />
    <Relation type="Alternative to" target="GPL18991" comment="Alternative CDF [HGU133A2_Hs_ENTREZG_16.0.0]" />
    <Relation type="Alternative to" target="GPL22932" comment="alternative" />
    <Data-Table>
      <Column position="1">
        <Name>ID</Name>
        <Description>Affymetrix Probe Set ID </Description>
        <Link-Prefix>https://www.affymetrix.com/LinkServlet?array=U133&amp;probeset=</Link-Prefix>
      </Column>
      <Column position="2">
        <Name>GB_ACC</Name>
        <Description>GenBank Accession Number </Description>
        <Link-Prefix>http://www.ncbi.nlm.nih.gov/nuccore/?term=</Link-Prefix>
      </Column>
      <Column position="3">
        <Name>SPOT_ID</Name>
        <Description>identifies controls</Description>
      </Column>
      <Column position="4">
        <Name>Species Scientific Name</Name>
        <Description>The genus and species of the organism represented by the probe set.</Description>
      </Column>
      <Column position="5">
        <Name>Annotation Date</Name>
        <Description>The date that the annotations for this probe array were last updated. It will generally be earlier than the date when the annotations were posted on the Affymetrix web site.</Description>
      </Column>
      <Column position="6">
        <Name>Sequence Type</Name>
      </Column>
      <Column position="7">
        <Name>Sequence Source</Name>
        <Description>The database from which the sequence used to design this probe set was taken.</Description>
      </Column>
      <Column position="8">
        <Name>Target Description</Name>
      </Column>
      <Column position="9">
        <Name>Representative Public ID</Name>
        <Description>The accession number of a representative sequence. Note that for consensus-based probe sets, the representative sequence is only one of several sequences (sequence sub-clusters) used to build the consensus sequence and it is not directly used to derive the probe sequences. The representative sequence is chosen during array design as a sequence that is best associated with the transcribed region being interrogated by the probe set. Refer to the &quot;Sequence Source&quot; field to determine the database used.</Description>
      </Column>
      <Column position="10">
        <Name>Gene Title</Name>
        <Description>Title of Gene represented by the probe set.</Description>
      </Column>
      <Column position="11">
        <Name>Gene Symbol</Name>
        <Description>A gene symbol, when one is available (from UniGene).</Description>
      </Column>
      <Column position="12">
        <Name>ENTREZ_GENE_ID</Name>
        <Description>Entrez Gene Database UID  </Description>
        <Link-Prefix>http://www.ncbi.nlm.nih.gov/gene/</Link-Prefix>
        <Link-Delimiter> /// </Link-Delimiter>
      </Column>
      <Column position="13">
        <Name>RefSeq Transcript ID</Name>
        <Description>References to multiple sequences in RefSeq. The field contains the ID and Description for each entry, and there can be multiple entries per ProbeSet.</Description>
      </Column>
      <Column position="14">
        <Name>Gene Ontology Biological Process</Name>
        <Description>Gene Ontology Consortium Biological Process derived from LocusLink.  Each annotation consists of three parts: &quot;Accession Number // Description // Evidence&quot;. The description corresponds directly to the GO ID. The evidence can be &quot;direct&quot;, or &quot;extended&quot;.</Description>
      </Column>
      <Column position="15">
        <Name>Gene Ontology Cellular Component</Name>
        <Description>Gene Ontology Consortium Cellular Component derived from LocusLink.  Each annotation consists of three parts: &quot;Accession Number // Description // Evidence&quot;. The description corresponds directly to the GO ID. The evidence can be &quot;direct&quot;, or &quot;extended&quot;.</Description>
      </Column>
      <Column position="16">
        <Name>Gene Ontology Molecular Function</Name>
        <Description>Gene Ontology Consortium Molecular Function derived from LocusLink.  Each annotation consists of three parts: &quot;Accession Number // Description // Evidence&quot;. The description corresponds directly to the GO ID. The evidence can be &quot;direct&quot;, or &quot;extended&quot;.</Description>
      </Column>
    <External-Data rows="22277">
GPL571-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Platform>

  <Platform iid="GPL1261">
    <Status database="GEO">
      <Submission-Date>2004-05-25</Submission-Date>
      <Release-Date>2004-05-25</Release-Date>
      <Last-Update-Date>2019-05-31</Last-Update-Date>
    </Status>
    <Title>[Mouse430_2] Affymetrix Mouse Genome 430 2.0 Array</Title>
    <Accession database="GEO">GPL1261</Accession>
    <Technology>in situ oligonucleotide</Technology>
    <Distribution>commercial</Distribution>
    <Organism taxid="10090">Mus musculus</Organism>
    <Manufacturer>Affymetrix</Manufacturer>
    <Manufacture-Protocol>
see manufacturer's web site

All probe sets represented on the GeneChip Mouse Expression Set 430 are included on the GeneChip Mouse Genome 430 2.0 Array. The sequences from which these probe sets were derived were selected from GenBank«, dbEST, and RefSeq. The sequence clusters were created from the UniGene database (Build 107, June 2002) and then refined by analysis and comparison with the publicly available draft assembly of the mouse genome from the Whitehead Institute for Genome Research (MGSC, April 2002).

    </Manufacture-Protocol>
    <Description>
Affymetrix submissions are typically submitted to GEO using the GEOarchive method described at http://www.ncbi.nlm.nih.gov/projects/geo/info/geo_affy.html

June 03, 2009: annotation table updated with netaffx build 28
June 07, 2012: annotation table updated with netaffx build 32
June 23, 2016: annotation table updated with netaffx build 35
    </Description>
    <Web-Link>http://www.affymetrix.com/support/technical/byproduct.affx?product=moe430-20</Web-Link>
    <Web-Link>http://www.affymetrix.com/analysis/index.affx</Web-Link>
    <Relation type="Alternative to" target="GPL5008" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL5766" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL5759" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL6456" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL6526" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL7368" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL7546" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL7635" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL6886" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL8059" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL8462" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL8492" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL9523" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL9746" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL10288" comment="Alternative CDF [Mm_ENTREZG_11]" />
    <Relation type="Alternative to" target="GPL10369" comment="Alternative CDF [Mm_Unigene_10]" />
    <Relation type="Alternative to" target="GPL10773" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL11044" comment="Alternative CDF [Mouse4302_Mm_REFSEQ]" />
    <Relation type="Alternative to" target="GPL14657" comment="Alternative CDF [Mouse4302_Mm_ENSG_13]" />
    <Relation type="Alternative to" target="GPL14661" comment="Alternative CDF [Mouse4302_Mm_EntrezG]" />
    <Relation type="Alternative to" target="GPL14757" comment="Alternative CDF [Mouse4302_Mm_REFSEQ_v11]" />
    <Relation type="Alternative to" target="GPL15041" comment="alternative CDF" />
    <Relation type="Alternative to" target="GPL15592" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL15967" comment="Alternative CDF" />
    <Relation type="Alternative to" target="GPL16225" comment="Alternative CDF [Mouse4302_Mm_ENTREZG_v14]" />
    <Relation type="Alternative to" target="GPL16368" comment="Alternative CDF [Mouse4302_Mm_ENTREZG_v16]" />
    <Relation type="Alternative to" target="GPL16582" comment="Alternative CDF [mouse4302daiplusv6cdf]" />
    <Relation type="Alternative to" target="GPL17114" />
    <Relation type="Alternative to" target="GPL18122" comment="custom CDF" />
    <Relation type="Alternative to" target="GPL18223" comment="Alternative CDF [Mouse4302_Mm_ENTREZG_v17.1.0]" />
    <Relation type="Alternative to" target="GPL18376" comment="Alternative CDF [Mouse4302_Mm_ENTREZG_12.1.0]" />
    <Relation type="Alternative to" target="GPL18416" comment="Alternative CDF [Mouse430A2_Mm_ENST_13.0.0]" />
    <Relation type="Alternative to" target="GPL18615 (Alternative CDF" comment="Mouse4302_Mm_ENTREZG_v17.0.0)" />
    <Relation type="Alternative to" target="GPL18854 (Alternative CDF" comment="Mouse4302_Mm_REFSEQ_v16.0.0)" />
    <Relation type="Alternative to" target="GPL19559" comment="Alternative CDF [Mouse4302_Mm_ENTREZG_18.0.0]" />
    <Relation type="Alternative to" target="GPL20766" comment="Alternative CDF [Mouse4302_Mm_ENSG_17.0.0]" />
    <Relation type="Alternative to" target="GPL22519" comment="Alternative CDF [Mouse4302_Mm_ENSG_19.0.0]" />
    <Relation type="Alternative to" target="GPL23097" comment="Alternative CDF [Mouse4302_Mm_ENTREZG_21.0.0]" />
    <Relation type="Alternative to" target="GPL26724" comment="Alternative CDF" />
    <Data-Table>
      <Column position="1">
        <Name>ID</Name>
        <Description>Affymetrix Probe Set ID </Description>
        <Link-Prefix>https://www.affymetrix.com/LinkServlet?array=MOE430&amp;probeset=</Link-Prefix>
      </Column>
      <Column position="2">
        <Name>GB_ACC</Name>
        <Description>GenBank Accession Number </Description>
        <Link-Prefix>http://www.ncbi.nlm.nih.gov/nuccore/?term=</Link-Prefix>
      </Column>
      <Column position="3">
        <Name>SPOT_ID</Name>
        <Description>identifies controls</Description>
      </Column>
      <Column position="4">
        <Name>Species Scientific Name</Name>
        <Description>The genus and species of the organism represented by the probe set.</Description>
      </Column>
      <Column position="5">
        <Name>Annotation Date</Name>
        <Description>The date that the annotations for this probe array were last updated. It will generally be earlier than the date when the annotations were posted on the Affymetrix web site.</Description>
      </Column>
      <Column position="6">
        <Name>Sequence Type</Name>
      </Column>
      <Column position="7">
        <Name>Sequence Source</Name>
        <Description>The database from which the sequence used to design this probe set was taken.</Description>
      </Column>
      <Column position="8">
        <Name>Target Description</Name>
      </Column>
      <Column position="9">
        <Name>Representative Public ID</Name>
        <Description>The accession number of a representative sequence. Note that for consensus-based probe sets, the representative sequence is only one of several sequences (sequence sub-clusters) used to build the consensus sequence and it is not directly used to derive the probe sequences. The representative sequence is chosen during array design as a sequence that is best associated with the transcribed region being interrogated by the probe set. Refer to the &quot;Sequence Source&quot; field to determine the database used.</Description>
      </Column>
      <Column position="10">
        <Name>Gene Title</Name>
        <Description>Title of Gene represented by the probe set.</Description>
      </Column>
      <Column position="11">
        <Name>Gene Symbol</Name>
        <Description>A gene symbol, when one is available (from UniGene).</Description>
      </Column>
      <Column position="12">
        <Name>ENTREZ_GENE_ID</Name>
        <Description>Entrez Gene Database UID  </Description>
        <Link-Prefix>http://www.ncbi.nlm.nih.gov/gene/</Link-Prefix>
        <Link-Delimiter> /// </Link-Delimiter>
      </Column>
      <Column position="13">
        <Name>RefSeq Transcript ID</Name>
        <Description>References to multiple sequences in RefSeq. The field contains the ID and Description for each entry, and there can be multiple entries per ProbeSet.</Description>
      </Column>
      <Column position="14">
        <Name>Gene Ontology Biological Process</Name>
        <Description>Gene Ontology Consortium Biological Process derived from LocusLink.  Each annotation consists of three parts: &quot;Accession Number // Description // Evidence&quot;. The description corresponds directly to the GO ID. The evidence can be &quot;direct&quot;, or &quot;extended&quot;.</Description>
      </Column>
      <Column position="15">
        <Name>Gene Ontology Cellular Component</Name>
        <Description>Gene Ontology Consortium Cellular Component derived from LocusLink.  Each annotation consists of three parts: &quot;Accession Number // Description // Evidence&quot;. The description corresponds directly to the GO ID. The evidence can be &quot;direct&quot;, or &quot;extended&quot;.</Description>
      </Column>
      <Column position="16">
        <Name>Gene Ontology Molecular Function</Name>
        <Description>Gene Ontology Consortium Molecular Function derived from LocusLink.  Each annotation consists of three parts: &quot;Accession Number // Description // Evidence&quot;. The description corresponds directly to the GO ID. The evidence can be &quot;direct&quot;, or &quot;extended&quot;.</Description>
      </Column>
    <External-Data rows="45101">
GPL1261-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Platform>

  <Sample iid="GSM824455">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood 129S1/SvImJ 0hrs rep1 batch 2 batch 2 1545_4182_21995_129-cont-1set</Title>
    <Accession database="GEO">GSM824455</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood 129S1/SvImJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
129S1/SvImJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824455/suppl/GSM824455_1545_4182_21995_129-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824455/suppl/GSM824455_1545_4182_21995_129-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824455-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824456">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood 129S1/SvImJ 0hrs rep2 batch 2 batch 2 1545_4182_22009_129-cont-2set</Title>
    <Accession database="GEO">GSM824456</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood 129S1/SvImJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
129S1/SvImJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824456/suppl/GSM824456_1545_4182_22009_129-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824456/suppl/GSM824456_1545_4182_22009_129-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824456-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824457">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood 129S1/SvImJ 0hrs rep3 batch 2 batch 2 1545_4182_22023_129-cont-3set</Title>
    <Accession database="GEO">GSM824457</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood 129S1/SvImJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
129S1/SvImJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824457/suppl/GSM824457_1545_4182_22023_129-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824457/suppl/GSM824457_1545_4182_22023_129-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824457-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824458">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood 129S1/SvImJ 2hrs Sanger rep1 batch 2 batch 2 1545_4182_21996_129-2h-1set</Title>
    <Accession database="GEO">GSM824458</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood 129S1/SvImJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
129S1/SvImJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824458/suppl/GSM824458_1545_4182_21996_129-2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824458/suppl/GSM824458_1545_4182_21996_129-2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824458-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824459">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood 129S1/SvImJ 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22010_129-2h-2set</Title>
    <Accession database="GEO">GSM824459</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood 129S1/SvImJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
129S1/SvImJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824459/suppl/GSM824459_1545_4182_22010_129-2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824459/suppl/GSM824459_1545_4182_22010_129-2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824459-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824460">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood 129S1/SvImJ 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22024_129-2h-3set</Title>
    <Accession database="GEO">GSM824460</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood 129S1/SvImJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
129S1/SvImJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824460/suppl/GSM824460_1545_4182_22024_129-2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824460/suppl/GSM824460_1545_4182_22024_129-2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824460-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824461">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep1 batch 6 batch 6 1545_4319_23514_AJ-control-2</Title>
    <Accession database="GEO">GSM824461</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824461/suppl/GSM824461_1545_4319_23514_AJ-control-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824461/suppl/GSM824461_1545_4319_23514_AJ-control-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824461-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824462">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep2 batch 6 batch 6 1545_4319_23517_AJ-control-3</Title>
    <Accession database="GEO">GSM824462</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824462/suppl/GSM824462_1545_4319_23517_AJ-control-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824462/suppl/GSM824462_1545_4319_23517_AJ-control-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824462-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824463">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep3 batch 6 batch 6 1545_4319_23524_AJ-control-5</Title>
    <Accession database="GEO">GSM824463</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824463/suppl/GSM824463_1545_4319_23524_AJ-control-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824463/suppl/GSM824463_1545_4319_23524_AJ-control-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824463-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824464">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep1 batch 1 batch 1 1545_3293_16118_1</Title>
    <Accession database="GEO">GSM824464</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824464/suppl/GSM824464_1545_3293_16118_1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824464/suppl/GSM824464_1545_3293_16118_1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824464-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824465">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep2 batch 1 batch 1 1545_3293_16119_2</Title>
    <Accession database="GEO">GSM824465</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824465/suppl/GSM824465_1545_3293_16119_2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824465/suppl/GSM824465_1545_3293_16119_2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824465-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824466">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep3 batch 1 batch 1 1545_3293_16120_3</Title>
    <Accession database="GEO">GSM824466</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824466/suppl/GSM824466_1545_3293_16120_3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824466/suppl/GSM824466_1545_3293_16120_3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824466-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824467">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep4 batch 1 batch 1 1545_3293_16121_6</Title>
    <Accession database="GEO">GSM824467</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824467/suppl/GSM824467_1545_3293_16121_6_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824467/suppl/GSM824467_1545_3293_16121_6_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824467-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824468">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep5 batch 1 batch 1 1545_3293_16122_7</Title>
    <Accession database="GEO">GSM824468</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824468/suppl/GSM824468_1545_3293_16122_7_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824468/suppl/GSM824468_1545_3293_16122_7_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824468-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824469">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep5 batch 2 batch 2 1545_3968_20724_6Acontrol</Title>
    <Accession database="GEO">GSM824469</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824469/suppl/GSM824469_1545_3968_20724_6Acontrol_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824469/suppl/GSM824469_1545_3968_20724_6Acontrol_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824469-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824470">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep1 batch 2 batch 2 1545_4008_20921_A1cont</Title>
    <Accession database="GEO">GSM824470</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824470/suppl/GSM824470_1545_4008_20921_A1cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824470/suppl/GSM824470_1545_4008_20921_A1cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824470-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824471">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep2 batch 2 batch 2 1545_4008_20931_A2cont</Title>
    <Accession database="GEO">GSM824471</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824471/suppl/GSM824471_1545_4008_20931_A2cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824471/suppl/GSM824471_1545_4008_20931_A2cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824471-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824472">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep3 batch 2 batch 2 1545_4008_20941_A3cont</Title>
    <Accession database="GEO">GSM824472</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824472/suppl/GSM824472_1545_4008_20941_A3cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824472/suppl/GSM824472_1545_4008_20941_A3cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824472-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824473">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep4 batch 2 batch 2 1545_4008_20951_A4cont</Title>
    <Accession database="GEO">GSM824473</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824473/suppl/GSM824473_1545_4008_20951_A4cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824473/suppl/GSM824473_1545_4008_20951_A4cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824473-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824474">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep1 batch 2 batch 2 1545_4182_21997_A-cont-1set</Title>
    <Accession database="GEO">GSM824474</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824474/suppl/GSM824474_1545_4182_21997_A-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824474/suppl/GSM824474_1545_4182_21997_A-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824474-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824475">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep2 batch 2 batch 2 1545_4182_22011_A-cont-2set</Title>
    <Accession database="GEO">GSM824475</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824475/suppl/GSM824475_1545_4182_22011_A-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824475/suppl/GSM824475_1545_4182_22011_A-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824475-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824476">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep3 batch 2 batch 2 1545_4182_22025_A-cont-3set</Title>
    <Accession database="GEO">GSM824476</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824476/suppl/GSM824476_1545_4182_22025_A-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824476/suppl/GSM824476_1545_4182_22025_A-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824476-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824477">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep1 batch 1 batch 1 1545_3617_18176_AE1</Title>
    <Accession database="GEO">GSM824477</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824477/suppl/GSM824477_1545_3617_18176_AE1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824477/suppl/GSM824477_1545_3617_18176_AE1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824477-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824478">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep2 batch 1 batch 1 1545_3617_18177_AE2</Title>
    <Accession database="GEO">GSM824478</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824478/suppl/GSM824478_1545_3617_18177_AE2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824478/suppl/GSM824478_1545_3617_18177_AE2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824478-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824479">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep3 batch 1 batch 1 1545_3617_18178_AE3</Title>
    <Accession database="GEO">GSM824479</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824479/suppl/GSM824479_1545_3617_18178_AE3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824479/suppl/GSM824479_1545_3617_18178_AE3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824479-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824480">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep4 batch 1 batch 1 1545_3617_18179_AE4</Title>
    <Accession database="GEO">GSM824480</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824480/suppl/GSM824480_1545_3617_18179_AE4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824480/suppl/GSM824480_1545_3617_18179_AE4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824480-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824481">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep5 batch 1 batch 1 1545_3617_18180_AE5</Title>
    <Accession database="GEO">GSM824481</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824481/suppl/GSM824481_1545_3617_18180_AE5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824481/suppl/GSM824481_1545_3617_18180_AE5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824481-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824482">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs MW2 rep1 batch 6 batch 6 1545_4319_23513_AJ-nw2-2</Title>
    <Accession database="GEO">GSM824482</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus MW2</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
MW2
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824482/suppl/GSM824482_1545_4319_23513_AJ-nw2-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824482/suppl/GSM824482_1545_4319_23513_AJ-nw2-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824482-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824483">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs MW2 rep2 batch 6 batch 6 1545_4319_23516_AJ-nw2-3</Title>
    <Accession database="GEO">GSM824483</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus MW2</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
MW2
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824483/suppl/GSM824483_1545_4319_23516_AJ-nw2-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824483/suppl/GSM824483_1545_4319_23516_AJ-nw2-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824483-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824484">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs MW2 rep3 batch 6 batch 6 1545_4319_23523_AJ-nw2-4</Title>
    <Accession database="GEO">GSM824484</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus MW2</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
MW2
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824484/suppl/GSM824484_1545_4319_23523_AJ-nw2-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824484/suppl/GSM824484_1545_4319_23523_AJ-nw2-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824484-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824485">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep1 batch 2 batch 2 1545_3968_20725_A2h-1set</Title>
    <Accession database="GEO">GSM824485</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824485/suppl/GSM824485_1545_3968_20725_A2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824485/suppl/GSM824485_1545_3968_20725_A2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824485-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824486">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep2 batch 2 batch 2 1545_4008_20930_A2h-2nd</Title>
    <Accession database="GEO">GSM824486</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824486/suppl/GSM824486_1545_4008_20930_A2h-2nd_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824486/suppl/GSM824486_1545_4008_20930_A2h-2nd_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824486-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824487">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep3 batch 2 batch 2 1545_4008_20933_A2h-3set</Title>
    <Accession database="GEO">GSM824487</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824487/suppl/GSM824487_1545_4008_20933_A2h-3set_Mouse430+2_2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824487/suppl/GSM824487_1545_4008_20933_A2h-3set_Mouse430+2_2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824487-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824488">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep4 batch 2 batch 2 1545_4008_20943_A2h-4set</Title>
    <Accession database="GEO">GSM824488</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824488/suppl/GSM824488_1545_4008_20943_A2h-4set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824488/suppl/GSM824488_1545_4008_20943_A2h-4set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824488-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824489">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep5 batch 2 batch 2 1545_4008_20953_A2h-5set</Title>
    <Accession database="GEO">GSM824489</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824489/suppl/GSM824489_1545_4008_20953_A2h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824489/suppl/GSM824489_1545_4008_20953_A2h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824489-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824490">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep1 batch 2 batch 2 1545_4182_21998_A2h-1set</Title>
    <Accession database="GEO">GSM824490</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824490/suppl/GSM824490_1545_4182_21998_A2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824490/suppl/GSM824490_1545_4182_21998_A2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824490-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824491">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22012_A2h-2set</Title>
    <Accession database="GEO">GSM824491</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824491/suppl/GSM824491_1545_4182_22012_A2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824491/suppl/GSM824491_1545_4182_22012_A2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824491-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824492">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22026_A2h-3set</Title>
    <Accession database="GEO">GSM824492</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824492/suppl/GSM824492_1545_4182_22026_A2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824492/suppl/GSM824492_1545_4182_22026_A2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824492-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824493">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep1 batch 6 batch 6 1545_4319_23512_AJ-sanger-2</Title>
    <Accession database="GEO">GSM824493</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824493/suppl/GSM824493_1545_4319_23512_AJ-sanger-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824493/suppl/GSM824493_1545_4319_23512_AJ-sanger-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824493-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824494">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep2 batch 6 batch 6 1545_4319_23515_AJ-sanger-3</Title>
    <Accession database="GEO">GSM824494</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824494/suppl/GSM824494_1545_4319_23515_AJ-sanger-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824494/suppl/GSM824494_1545_4319_23515_AJ-sanger-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824494-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824495">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Sanger rep3 batch 6 batch 6 1545_4319_23522_AJ-sanger-5</Title>
    <Accession database="GEO">GSM824495</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824495/suppl/GSM824495_1545_4319_23522_AJ-sanger-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824495/suppl/GSM824495_1545_4319_23522_AJ-sanger-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824495-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824496">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 4hrs Sanger rep1 batch 2 batch 2 1545_3968_20726_A4h-1set</Title>
    <Accession database="GEO">GSM824496</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824496/suppl/GSM824496_1545_3968_20726_A4h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824496/suppl/GSM824496_1545_3968_20726_A4h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824496-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824497">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 4hrs Sanger rep2 batch 2 batch 2 1545_4008_20922_A4h-2set</Title>
    <Accession database="GEO">GSM824497</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824497/suppl/GSM824497_1545_4008_20922_A4h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824497/suppl/GSM824497_1545_4008_20922_A4h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824497-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824498">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 4hrs Sanger rep3 batch 2 batch 2 1545_4008_20934_A4h-3set</Title>
    <Accession database="GEO">GSM824498</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824498/suppl/GSM824498_1545_4008_20934_A4h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824498/suppl/GSM824498_1545_4008_20934_A4h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824498-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824499">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 4hrs Sanger rep4 batch 2 batch 2 1545_4008_20944_A4h-4set</Title>
    <Accession database="GEO">GSM824499</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824499/suppl/GSM824499_1545_4008_20944_A4h-4set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824499/suppl/GSM824499_1545_4008_20944_A4h-4set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824499-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824500">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 4hrs Sanger rep5 batch 2 batch 2 1545_4008_20954_A4h-5set</Title>
    <Accession database="GEO">GSM824500</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824500/suppl/GSM824500_1545_4008_20954_A4h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824500/suppl/GSM824500_1545_4008_20954_A4h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824500-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824501">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Sanger rep1 batch 2 batch 2 1545_3968_20727_A6h-1set</Title>
    <Accession database="GEO">GSM824501</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824501/suppl/GSM824501_1545_3968_20727_A6h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824501/suppl/GSM824501_1545_3968_20727_A6h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824501-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824502">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Sanger rep2 batch 2 batch 2 1545_4008_20923_A6h-2set</Title>
    <Accession database="GEO">GSM824502</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824502/suppl/GSM824502_1545_4008_20923_A6h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824502/suppl/GSM824502_1545_4008_20923_A6h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824502-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824503">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Sanger rep3 batch 2 batch 2 1545_4008_20935_A6h-3set</Title>
    <Accession database="GEO">GSM824503</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824503/suppl/GSM824503_1545_4008_20935_A6h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824503/suppl/GSM824503_1545_4008_20935_A6h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824503-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824504">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Sanger rep4 batch 2 batch 2 1545_4008_20945_A6h-4set</Title>
    <Accession database="GEO">GSM824504</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824504/suppl/GSM824504_1545_4008_20945_A6h-4set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824504/suppl/GSM824504_1545_4008_20945_A6h-4set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824504-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824505">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Sanger rep5 batch 2 batch 2 1545_4008_20955_A6h-5set</Title>
    <Accession database="GEO">GSM824505</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824505/suppl/GSM824505_1545_4008_20955_A6h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824505/suppl/GSM824505_1545_4008_20955_A6h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824505-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824506">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep1 batch 2 batch 2 1545_3968_20728_A12h-1set</Title>
    <Accession database="GEO">GSM824506</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824506/suppl/GSM824506_1545_3968_20728_A12h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824506/suppl/GSM824506_1545_3968_20728_A12h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824506-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824507">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep2 batch 2 batch 2 1545_4008_20924_A12h-2set</Title>
    <Accession database="GEO">GSM824507</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824507/suppl/GSM824507_1545_4008_20924_A12h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824507/suppl/GSM824507_1545_4008_20924_A12h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824507-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824508">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep3 batch 2 batch 2 1545_4008_20936_A12h-3set</Title>
    <Accession database="GEO">GSM824508</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824508/suppl/GSM824508_1545_4008_20936_A12h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824508/suppl/GSM824508_1545_4008_20936_A12h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824508-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824509">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep4 batch 2 batch 2 1545_4008_20946_A12h-4set</Title>
    <Accession database="GEO">GSM824509</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824509/suppl/GSM824509_1545_4008_20946_A12h-4set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824509/suppl/GSM824509_1545_4008_20946_A12h-4set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824509-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824510">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep5 batch 2 batch 2 1545_4008_20956_A12h-5set</Title>
    <Accession database="GEO">GSM824510</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824510/suppl/GSM824510_1545_4008_20956_A12h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824510/suppl/GSM824510_1545_4008_20956_A12h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824510-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824511">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep1 batch 1 batch 1 1545_3293_16128_36</Title>
    <Accession database="GEO">GSM824511</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824511/suppl/GSM824511_1545_3293_16128_36_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824511/suppl/GSM824511_1545_3293_16128_36_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824511-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824512">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep2 batch 1 batch 1 1545_3293_16129_37</Title>
    <Accession database="GEO">GSM824512</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824512/suppl/GSM824512_1545_3293_16129_37_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824512/suppl/GSM824512_1545_3293_16129_37_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824512-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824513">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep3 batch 1 batch 1 1545_3293_16130_38</Title>
    <Accession database="GEO">GSM824513</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824513/suppl/GSM824513_1545_3293_16130_38_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824513/suppl/GSM824513_1545_3293_16130_38_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824513-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824514">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep4 batch 1 batch 1 1545_3293_16131_39</Title>
    <Accession database="GEO">GSM824514</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824514/suppl/GSM824514_1545_3293_16131_39_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824514/suppl/GSM824514_1545_3293_16131_39_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824514-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824515">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Sanger rep5 batch 1 batch 1 1545_3293_16137_40</Title>
    <Accession database="GEO">GSM824515</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824515/suppl/GSM824515_1545_3293_16137_40_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824515/suppl/GSM824515_1545_3293_16137_40_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824515-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824516">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs USA100 rep1 batch 6 batch 6 1545_4319_23511_AJ-usa-100-2</Title>
    <Accession database="GEO">GSM824516</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus USA100</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA100
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824516/suppl/GSM824516_1545_4319_23511_AJ-usa-100-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824516/suppl/GSM824516_1545_4319_23511_AJ-usa-100-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824516-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824517">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs USA100 rep2 batch 6 batch 6 1545_4319_23519_AJ-usa-100-4</Title>
    <Accession database="GEO">GSM824517</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus USA100</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA100
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824517/suppl/GSM824517_1545_4319_23519_AJ-usa-100-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824517/suppl/GSM824517_1545_4319_23519_AJ-usa-100-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824517-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824518">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs USA100 rep3 batch 6 batch 6 1545_4319_23521_AJ-usa-100-5</Title>
    <Accession database="GEO">GSM824518</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus USA100</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA100
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824518/suppl/GSM824518_1545_4319_23521_AJ-usa-100-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824518/suppl/GSM824518_1545_4319_23521_AJ-usa-100-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824518-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824519">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs USA300 rep1 batch 6 batch 6 1545_4319_23510_AJ-usa-300-2</Title>
    <Accession database="GEO">GSM824519</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824519/suppl/GSM824519_1545_4319_23510_AJ-usa-300-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824519/suppl/GSM824519_1545_4319_23510_AJ-usa-300-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824519-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824520">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs USA300 rep2 batch 6 batch 6 1545_4319_23518_AJ-usa-300-4</Title>
    <Accession database="GEO">GSM824520</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824520/suppl/GSM824520_1545_4319_23518_AJ-usa-300-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824520/suppl/GSM824520_1545_4319_23518_AJ-usa-300-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824520-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824521">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs USA300 rep3 batch 6 batch 6 1545_4319_23520_AJ-usa-300-5</Title>
    <Accession database="GEO">GSM824521</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
6
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824521/suppl/GSM824521_1545_4319_23520_AJ-usa-300-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824521/suppl/GSM824521_1545_4319_23520_AJ-usa-300-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824521-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824522">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood AKR/J 0hrs rep1 batch 2 batch 2 1545_4182_21999_AKR-cont-1set</Title>
    <Accession database="GEO">GSM824522</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood AKR/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
AKR/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824522/suppl/GSM824522_1545_4182_21999_AKR-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824522/suppl/GSM824522_1545_4182_21999_AKR-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824522-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824523">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood AKR/J 0hrs rep2 batch 2 batch 2 1545_4182_22013_AKR-cont-2set</Title>
    <Accession database="GEO">GSM824523</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood AKR/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
AKR/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824523/suppl/GSM824523_1545_4182_22013_AKR-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824523/suppl/GSM824523_1545_4182_22013_AKR-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824523-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824524">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood AKR/J 0hrs rep3 batch 2 batch 2 1545_4182_22027_AKR-cont-3set</Title>
    <Accession database="GEO">GSM824524</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood AKR/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
AKR/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824524/suppl/GSM824524_1545_4182_22027_AKR-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824524/suppl/GSM824524_1545_4182_22027_AKR-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824524-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824525">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood AKR/J 2hrs Sanger rep1 batch 2 batch 2 1545_4182_22000_AKR-2h-1set</Title>
    <Accession database="GEO">GSM824525</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood AKR/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
AKR/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824525/suppl/GSM824525_1545_4182_22000_AKR-2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824525/suppl/GSM824525_1545_4182_22000_AKR-2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824525-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824526">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood AKR/J 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22014_AKR-2h-2set</Title>
    <Accession database="GEO">GSM824526</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood AKR/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
AKR/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824526/suppl/GSM824526_1545_4182_22014_AKR-2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824526/suppl/GSM824526_1545_4182_22014_AKR-2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824526-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824527">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood AKR/J 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22028_AKR-2h-3set</Title>
    <Accession database="GEO">GSM824527</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood AKR/J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
AKR/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824527/suppl/GSM824527_1545_4182_22028_AKR-2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824527/suppl/GSM824527_1545_4182_22028_AKR-2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824527-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824528">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood BALB/cByJ 0hrs rep1 batch 2 batch 2 1545_4182_22001_BALB-cont-1set</Title>
    <Accession database="GEO">GSM824528</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood BALB/cBy mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
BALB/cByJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824528/suppl/GSM824528_1545_4182_22001_BALB-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824528/suppl/GSM824528_1545_4182_22001_BALB-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824528-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824529">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood BALB/cByJ 0hrs rep2 batch 2 batch 2 1545_4182_22015_BALB-cont-2set</Title>
    <Accession database="GEO">GSM824529</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood BALB/cBy mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
BALB/cByJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824529/suppl/GSM824529_1545_4182_22015_BALB-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824529/suppl/GSM824529_1545_4182_22015_BALB-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824529-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824530">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood BALB/cByJ 0hrs rep3 batch 2 batch 2 1545_4182_22029_BALB-cont-3set</Title>
    <Accession database="GEO">GSM824530</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood BALB/cBy mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
BALB/cByJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824530/suppl/GSM824530_1545_4182_22029_BALB-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824530/suppl/GSM824530_1545_4182_22029_BALB-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824530-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824531">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood BALB/cByJ 2hrs Sanger rep1 batch 2 batch 2 1545_4182_22002_BALB-2h-1set</Title>
    <Accession database="GEO">GSM824531</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood BALB/cBy mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
BALB/cByJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824531/suppl/GSM824531_1545_4182_22002_BALB-2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824531/suppl/GSM824531_1545_4182_22002_BALB-2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824531-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824532">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood BALB/cByJ 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22016_BALB-2h-2set</Title>
    <Accession database="GEO">GSM824532</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood BALB/cBy mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
BALB/cByJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824532/suppl/GSM824532_1545_4182_22016_BALB-2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824532/suppl/GSM824532_1545_4182_22016_BALB-2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824532-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824533">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood BALB/cByJ 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22030_BALB-2h-3set</Title>
    <Accession database="GEO">GSM824533</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood BALB/cBy mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
BALB/cByJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824533/suppl/GSM824533_1545_4182_22030_BALB-2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824533/suppl/GSM824533_1545_4182_22030_BALB-2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824533-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824534">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C3H/HeJ 0hrs rep1 batch 2 batch 2 1545_4182_22005_C3H-cont-1set</Title>
    <Accession database="GEO">GSM824534</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C3H/HeJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C3H/HeJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824534/suppl/GSM824534_1545_4182_22005_C3H-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824534/suppl/GSM824534_1545_4182_22005_C3H-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824534-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824535">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C3H/HeJ 0hrs rep2 batch 2 batch 2 1545_4182_22019_C3H-cont-2set</Title>
    <Accession database="GEO">GSM824535</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C3H/HeJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C3H/HeJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824535/suppl/GSM824535_1545_4182_22019_C3H-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824535/suppl/GSM824535_1545_4182_22019_C3H-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824535-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824536">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C3H/HeJ 0hrs rep3 batch 2 batch 2 1545_4182_22033_C3H-cont-3set</Title>
    <Accession database="GEO">GSM824536</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C3H/HeJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C3H/HeJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824536/suppl/GSM824536_1545_4182_22033_C3H-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824536/suppl/GSM824536_1545_4182_22033_C3H-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824536-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824537">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C3H/HeJ 2hrs Sanger rep1 batch 2 batch 2 1545_4182_22006_C3H-2h-1set</Title>
    <Accession database="GEO">GSM824537</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C3H/HeJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C3H/HeJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824537/suppl/GSM824537_1545_4182_22006_C3H-2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824537/suppl/GSM824537_1545_4182_22006_C3H-2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824537-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824538">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C3H/HeJ 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22020_C3H-2h-2set</Title>
    <Accession database="GEO">GSM824538</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C3H/HeJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C3H/HeJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824538/suppl/GSM824538_1545_4182_22020_C3H-2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824538/suppl/GSM824538_1545_4182_22020_C3H-2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824538-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824539">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C3H/HeJ 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22034_C3H-2h-3set</Title>
    <Accession database="GEO">GSM824539</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C3H/HeJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C3H/HeJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824539/suppl/GSM824539_1545_4182_22034_C3H-2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824539/suppl/GSM824539_1545_4182_22034_C3H-2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824539-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824540">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Sanger rep1 batch 2 batch 2 1545_4182_22004_B2h-1set</Title>
    <Accession database="GEO">GSM824540</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824540/suppl/GSM824540_1545_4182_22004_B2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824540/suppl/GSM824540_1545_4182_22004_B2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824540-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824541">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22018_B2h-2set</Title>
    <Accession database="GEO">GSM824541</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824541/suppl/GSM824541_1545_4182_22018_B2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824541/suppl/GSM824541_1545_4182_22018_B2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824541-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824542">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22032_B2h-3set</Title>
    <Accession database="GEO">GSM824542</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger479
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824542/suppl/GSM824542_1545_4182_22032_B2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824542/suppl/GSM824542_1545_4182_22032_B2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824542-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824543">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep1 batch 1 batch 1 1545_3293_16114_16</Title>
    <Accession database="GEO">GSM824543</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824543/suppl/GSM824543_1545_3293_16114_16_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824543/suppl/GSM824543_1545_3293_16114_16_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824543-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824544">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep2 batch 1 batch 1 1545_3293_16115_17</Title>
    <Accession database="GEO">GSM824544</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824544/suppl/GSM824544_1545_3293_16115_17_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824544/suppl/GSM824544_1545_3293_16115_17_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824544-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824545">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep3 batch 1 batch 1 1545_3293_16116_18</Title>
    <Accession database="GEO">GSM824545</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824545/suppl/GSM824545_1545_3293_16116_18_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824545/suppl/GSM824545_1545_3293_16116_18_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824545-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824546">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep4 batch 1 batch 1 1545_3293_16117_19</Title>
    <Accession database="GEO">GSM824546</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824546/suppl/GSM824546_1545_3293_16117_19_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824546/suppl/GSM824546_1545_3293_16117_19_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824546-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824547">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep5 batch 1 batch 1 1545_3293_16123_20</Title>
    <Accession database="GEO">GSM824547</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824547/suppl/GSM824547_1545_3293_16123_20_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824547/suppl/GSM824547_1545_3293_16123_20_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824547-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824548">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep5 batch 2 batch 2 1545_3967_20733_18Bcontrol</Title>
    <Accession database="GEO">GSM824548</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824548/suppl/GSM824548_1545_3967_20733_18Bcontrol_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824548/suppl/GSM824548_1545_3967_20733_18Bcontrol_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824548-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824549">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep1 batch 2 batch 2 1545_4008_20926_B1cont</Title>
    <Accession database="GEO">GSM824549</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824549/suppl/GSM824549_1545_4008_20926_B1cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824549/suppl/GSM824549_1545_4008_20926_B1cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824549-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824550">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep2 batch 2 batch 2 1545_4008_20932_B2cont</Title>
    <Accession database="GEO">GSM824550</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824550/suppl/GSM824550_1545_4008_20932_B2cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824550/suppl/GSM824550_1545_4008_20932_B2cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824550-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824551">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep3 batch 2 batch 2 1545_4008_20942_B3cont</Title>
    <Accession database="GEO">GSM824551</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824551/suppl/GSM824551_1545_4008_20942_B3cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824551/suppl/GSM824551_1545_4008_20942_B3cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824551-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824552">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep4 batch 2 batch 2 1545_4008_20952_B4cont</Title>
    <Accession database="GEO">GSM824552</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824552/suppl/GSM824552_1545_4008_20952_B4cont_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824552/suppl/GSM824552_1545_4008_20952_B4cont_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824552-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824553">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep1 batch 2 batch 2 1545_4182_22003_B-cont-1set</Title>
    <Accession database="GEO">GSM824553</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824553/suppl/GSM824553_1545_4182_22003_B-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824553/suppl/GSM824553_1545_4182_22003_B-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824553-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824554">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep2 batch 2 batch 2 1545_4182_22017_B-cont-2set</Title>
    <Accession database="GEO">GSM824554</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824554/suppl/GSM824554_1545_4182_22017_B-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824554/suppl/GSM824554_1545_4182_22017_B-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824554-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824555">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep3 batch 2 batch 2 1545_4182_22031_B-cont-3set</Title>
    <Accession database="GEO">GSM824555</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824555/suppl/GSM824555_1545_4182_22031_B-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824555/suppl/GSM824555_1545_4182_22031_B-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824555-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824556">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep1 batch 1 batch 1 1545_3617_18181_BE1</Title>
    <Accession database="GEO">GSM824556</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824556/suppl/GSM824556_1545_3617_18181_BE1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824556/suppl/GSM824556_1545_3617_18181_BE1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824556-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824557">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep2 batch 1 batch 1 1545_3617_18182_BE2</Title>
    <Accession database="GEO">GSM824557</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824557/suppl/GSM824557_1545_3617_18182_BE2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824557/suppl/GSM824557_1545_3617_18182_BE2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824557-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824558">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep3 batch 1 batch 1 1545_3617_18183_BE3</Title>
    <Accession database="GEO">GSM824558</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824558/suppl/GSM824558_1545_3617_18183_BE3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824558/suppl/GSM824558_1545_3617_18183_BE3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824558-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824559">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep4 batch 1 batch 1 1545_3617_18184_BE4</Title>
    <Accession database="GEO">GSM824559</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824559/suppl/GSM824559_1545_3617_18184_BE4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824559/suppl/GSM824559_1545_3617_18184_BE4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824559-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824560">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep5 batch 1 batch 1 1545_3617_18185_BE5</Title>
    <Accession database="GEO">GSM824560</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824560/suppl/GSM824560_1545_3617_18185_BE5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824560/suppl/GSM824560_1545_3617_18185_BE5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824560-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824561">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Sanger rep1 batch 2 batch 2 1545_3968_20729_B2h-1set</Title>
    <Accession database="GEO">GSM824561</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824561/suppl/GSM824561_1545_3968_20729_B2h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824561/suppl/GSM824561_1545_3968_20729_B2h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824561-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824562">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Sanger rep2 batch 2 batch 2 1545_4008_20927_B2h-2set</Title>
    <Accession database="GEO">GSM824562</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824562/suppl/GSM824562_1545_4008_20927_B2h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824562/suppl/GSM824562_1545_4008_20927_B2h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824562-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824563">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Sanger rep3 batch 2 batch 2 1545_4008_20937_B2h-3set</Title>
    <Accession database="GEO">GSM824563</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824563/suppl/GSM824563_1545_4008_20937_B2h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824563/suppl/GSM824563_1545_4008_20937_B2h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824563-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824564">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Sanger rep4 batch 2 batch 2 1545_4008_20947_B2h-4set</Title>
    <Accession database="GEO">GSM824564</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824564/suppl/GSM824564_1545_4008_20947_B2h-4set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824564/suppl/GSM824564_1545_4008_20947_B2h-4set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824564-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824565">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Sanger rep5 batch 2 batch 2 1545_4008_20957_B2h-5set</Title>
    <Accession database="GEO">GSM824565</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824565/suppl/GSM824565_1545_4008_20957_B2h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824565/suppl/GSM824565_1545_4008_20957_B2h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824565-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824566">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 4hrs Sanger rep1 batch 2 batch 2 1545_3968_20730_B4h-1set</Title>
    <Accession database="GEO">GSM824566</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824566/suppl/GSM824566_1545_3968_20730_B4h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824566/suppl/GSM824566_1545_3968_20730_B4h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824566-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824567">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 4hrs Sanger rep2 batch 2 batch 2 1545_4008_20925_B4h-2set</Title>
    <Accession database="GEO">GSM824567</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824567/suppl/GSM824567_1545_4008_20925_B4h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824567/suppl/GSM824567_1545_4008_20925_B4h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824567-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824568">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 4hrs Sanger rep3 batch 2 batch 2 1545_4008_20938_B4h-3set</Title>
    <Accession database="GEO">GSM824568</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824568/suppl/GSM824568_1545_4008_20938_B4h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824568/suppl/GSM824568_1545_4008_20938_B4h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824568-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824569">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 4hrs Sanger rep4 batch 2 batch 2 1545_4008_20948_B4h-4set</Title>
    <Accession database="GEO">GSM824569</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824569/suppl/GSM824569_1545_4008_20948_B4h-4set_Mouse430+2_2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824569/suppl/GSM824569_1545_4008_20948_B4h-4set_Mouse430+2_2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824569-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824570">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 4hrs Sanger rep5 batch 2 batch 2 1545_4008_20958_B4h-5set</Title>
    <Accession database="GEO">GSM824570</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 4 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
4
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824570/suppl/GSM824570_1545_4008_20958_B4h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824570/suppl/GSM824570_1545_4008_20958_B4h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824570-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824571">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Sanger rep1 batch 2 batch 2 1545_3968_20731_B6h-1set</Title>
    <Accession database="GEO">GSM824571</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824571/suppl/GSM824571_1545_3968_20731_B6h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824571/suppl/GSM824571_1545_3968_20731_B6h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824571-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824572">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Sanger rep2 batch 2 batch 2 1545_4008_20928_B6h-2set</Title>
    <Accession database="GEO">GSM824572</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824572/suppl/GSM824572_1545_4008_20928_B6h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824572/suppl/GSM824572_1545_4008_20928_B6h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824572-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824573">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Sanger rep3 batch 2 batch 2 1545_4008_20939_B6h-3set</Title>
    <Accession database="GEO">GSM824573</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824573/suppl/GSM824573_1545_4008_20939_B6h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824573/suppl/GSM824573_1545_4008_20939_B6h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824573-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824574">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Sanger rep4 batch 2 batch 2 1545_4008_20949_B6h-4set</Title>
    <Accession database="GEO">GSM824574</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824574/suppl/GSM824574_1545_4008_20949_B6h-4set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824574/suppl/GSM824574_1545_4008_20949_B6h-4set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824574-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824575">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Sanger rep5 batch 2 batch 2 1545_4008_20959_B6h-5set</Title>
    <Accession database="GEO">GSM824575</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824575/suppl/GSM824575_1545_4008_20959_B6h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824575/suppl/GSM824575_1545_4008_20959_B6h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824575-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824576">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep1 batch 2 batch 2 1545_3968_20732_B12h-1set</Title>
    <Accession database="GEO">GSM824576</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824576/suppl/GSM824576_1545_3968_20732_B12h-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824576/suppl/GSM824576_1545_3968_20732_B12h-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824576-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824577">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep2 batch 2 batch 2 1545_4008_20929_B12h-2set</Title>
    <Accession database="GEO">GSM824577</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824577/suppl/GSM824577_1545_4008_20929_B12h-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824577/suppl/GSM824577_1545_4008_20929_B12h-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824577-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824578">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep3 batch 2 batch 2 1545_4008_20940_B12h-3set</Title>
    <Accession database="GEO">GSM824578</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824578/suppl/GSM824578_1545_4008_20940_B12h-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824578/suppl/GSM824578_1545_4008_20940_B12h-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824578-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824579">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep4 batch 2 batch 2 1545_4008_20950_B12h-6set</Title>
    <Accession database="GEO">GSM824579</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824579/suppl/GSM824579_1545_4008_20950_B12h-6set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824579/suppl/GSM824579_1545_4008_20950_B12h-6set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824579-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824580">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep5 batch 2 batch 2 1545_4008_20960_B12h-5set</Title>
    <Accession database="GEO">GSM824580</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824580/suppl/GSM824580_1545_4008_20960_B12h-5set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824580/suppl/GSM824580_1545_4008_20960_B12h-5set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824580-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824581">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep2 batch 1 batch 1 1545_3293_16132_46</Title>
    <Accession database="GEO">GSM824581</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824581/suppl/GSM824581_1545_3293_16132_46_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824581/suppl/GSM824581_1545_3293_16132_46_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824581-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824582">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep3 batch 1 batch 1 1545_3293_16133_47</Title>
    <Accession database="GEO">GSM824582</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824582/suppl/GSM824582_1545_3293_16133_47_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824582/suppl/GSM824582_1545_3293_16133_47_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824582-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824583">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep4 batch 1 batch 1 1545_3293_16134_48</Title>
    <Accession database="GEO">GSM824583</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824583/suppl/GSM824583_1545_3293_16134_48_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824583/suppl/GSM824583_1545_3293_16134_48_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824583-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824584">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep5 batch 1 batch 1 1545_3293_16135_49</Title>
    <Accession database="GEO">GSM824584</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824584/suppl/GSM824584_1545_3293_16135_49_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824584/suppl/GSM824584_1545_3293_16135_49_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824584-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824585">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Sanger rep1 batch 1 batch 1 1545_3293_16136_45</Title>
    <Accession database="GEO">GSM824585</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
1
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824585/suppl/GSM824585_1545_3293_16136_45_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824585/suppl/GSM824585_1545_3293_16136_45_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824585-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824586">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood NOD/ShiLtJ 0hrs rep1 batch 2 batch 2 1545_4182_22007_NOD-cont-1set</Title>
    <Accession database="GEO">GSM824586</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood NOD/ShiLtJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
NOD/ShiLtJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824586/suppl/GSM824586_1545_4182_22007_NOD-cont-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824586/suppl/GSM824586_1545_4182_22007_NOD-cont-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824586-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824587">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood NOD/ShiLtJ 0hrs rep2 batch 2 batch 2 1545_4182_22021_NOD-cont-2set</Title>
    <Accession database="GEO">GSM824587</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood NOD/ShiLtJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
NOD/ShiLtJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824587/suppl/GSM824587_1545_4182_22021_NOD-cont-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824587/suppl/GSM824587_1545_4182_22021_NOD-cont-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824587-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824588">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood NOD/ShiLtJ 0hrs rep3 batch 2 batch 2 1545_4182_22035_NOD-cont-3set</Title>
    <Accession database="GEO">GSM824588</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood NOD/ShiLtJ mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
NOD/ShiLtJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824588/suppl/GSM824588_1545_4182_22035_NOD-cont-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824588/suppl/GSM824588_1545_4182_22035_NOD-cont-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824588-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824589">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood NOD/ShiLtJ 2hrs Sanger rep1 batch 2 batch 2 1545_4182_22008_NOD-2ht-1set</Title>
    <Accession database="GEO">GSM824589</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood NOD/ShiLtJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
NOD/ShiLtJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824589/suppl/GSM824589_1545_4182_22008_NOD-2ht-1set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824589/suppl/GSM824589_1545_4182_22008_NOD-2ht-1set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824589-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824590">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood NOD/ShiLtJ 2hrs Sanger rep2 batch 2 batch 2 1545_4182_22022_NOD-2ht-2set</Title>
    <Accession database="GEO">GSM824590</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood NOD/ShiLtJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
NOD/ShiLtJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824590/suppl/GSM824590_1545_4182_22022_NOD-2ht-2set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824590/suppl/GSM824590_1545_4182_22022_NOD-2ht-2set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824590-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824591">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood NOD/ShiLtJ 2hrs Sanger rep3 batch 2 batch 2 1545_4182_22036_NOD-2ht-3set</Title>
    <Accession database="GEO">GSM824591</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood NOD/ShiLtJ mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
NOD/ShiLtJ
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
2
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824591/suppl/GSM824591_1545_4182_22036_NOD-2ht-3set_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824591/suppl/GSM824591_1545_4182_22036_NOD-2ht-3set_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824591-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824592">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep1 batch 8 batch 8 1545_6512_31094_AJEcol0h-1</Title>
    <Accession database="GEO">GSM824592</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824592/suppl/GSM824592_1545_6512_31094_AJEcol0h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824592/suppl/GSM824592_1545_6512_31094_AJEcol0h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824592-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824593">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Ecoli rep1 batch 8 batch 8 1545_6512_31095_AJEcol2h-1</Title>
    <Accession database="GEO">GSM824593</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824593/suppl/GSM824593_1545_6512_31095_AJEcol2h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824593/suppl/GSM824593_1545_6512_31095_AJEcol2h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824593-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824594">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Ecoli rep1 batch 8 batch 8 1545_6512_31096_AJEcol6h-1</Title>
    <Accession database="GEO">GSM824594</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824594/suppl/GSM824594_1545_6512_31096_AJEcol6h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824594/suppl/GSM824594_1545_6512_31096_AJEcol6h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824594-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824595">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Ecoli rep1 batch 8 batch 8 1545_6512_31097_AJEcol12h-1</Title>
    <Accession database="GEO">GSM824595</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824595/suppl/GSM824595_1545_6512_31097_AJEcol12h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824595/suppl/GSM824595_1545_6512_31097_AJEcol12h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824595-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824596">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep1 batch 8 batch 8 1545_6512_31098_AJEcol24h-1</Title>
    <Accession database="GEO">GSM824596</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824596/suppl/GSM824596_1545_6512_31098_AJEcol24h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824596/suppl/GSM824596_1545_6512_31098_AJEcol24h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824596-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824597">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep1 batch 8 batch 8 1545_6512_31099_BLEcol0h-1</Title>
    <Accession database="GEO">GSM824597</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824597/suppl/GSM824597_1545_6512_31099_BLEcol0h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824597/suppl/GSM824597_1545_6512_31099_BLEcol0h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824597-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824598">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Ecoli rep1 batch 8 batch 8 1545_6512_31100_BLEcol2h-1</Title>
    <Accession database="GEO">GSM824598</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824598/suppl/GSM824598_1545_6512_31100_BLEcol2h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824598/suppl/GSM824598_1545_6512_31100_BLEcol2h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824598-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824599">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Ecoli rep1 batch 8 batch 8 1545_6512_31101_BLEcol6h-1</Title>
    <Accession database="GEO">GSM824599</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824599/suppl/GSM824599_1545_6512_31101_BLEcol6h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824599/suppl/GSM824599_1545_6512_31101_BLEcol6h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824599-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824600">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Ecoli rep1 batch 8 batch 8 1545_6512_31102_BLEcol12h-1</Title>
    <Accession database="GEO">GSM824600</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824600/suppl/GSM824600_1545_6512_31102_BLEcol12h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824600/suppl/GSM824600_1545_6512_31102_BLEcol12h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824600-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824601">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep1 batch 8 batch 8 1545_6512_31103_BLEcol24h-1</Title>
    <Accession database="GEO">GSM824601</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824601/suppl/GSM824601_1545_6512_31103_BLEcol24h-1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824601/suppl/GSM824601_1545_6512_31103_BLEcol24h-1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824601-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824602">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep2 batch 8 batch 8 1545_6512_31104_AJEcol0h-2</Title>
    <Accession database="GEO">GSM824602</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824602/suppl/GSM824602_1545_6512_31104_AJEcol0h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824602/suppl/GSM824602_1545_6512_31104_AJEcol0h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824602-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824603">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Ecoli rep2 batch 8 batch 8 1545_6512_31105_AJEcol2h-2</Title>
    <Accession database="GEO">GSM824603</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824603/suppl/GSM824603_1545_6512_31105_AJEcol2h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824603/suppl/GSM824603_1545_6512_31105_AJEcol2h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824603-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824604">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Ecoli rep2 batch 8 batch 8 1545_6512_31106_AJEcol6h-2</Title>
    <Accession database="GEO">GSM824604</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824604/suppl/GSM824604_1545_6512_31106_AJEcol6h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824604/suppl/GSM824604_1545_6512_31106_AJEcol6h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824604-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824605">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Ecoli rep2 batch 8 batch 8 1545_6512_31107_AJEcol12h-2</Title>
    <Accession database="GEO">GSM824605</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824605/suppl/GSM824605_1545_6512_31107_AJEcol12h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824605/suppl/GSM824605_1545_6512_31107_AJEcol12h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824605-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824606">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep2 batch 8 batch 8 1545_6512_31108_AJEcol24h-2</Title>
    <Accession database="GEO">GSM824606</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824606/suppl/GSM824606_1545_6512_31108_AJEcol24h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824606/suppl/GSM824606_1545_6512_31108_AJEcol24h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824606-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824607">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep2 batch 8 batch 8 1545_6512_31109_BLEcol0h-2</Title>
    <Accession database="GEO">GSM824607</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824607/suppl/GSM824607_1545_6512_31109_BLEcol0h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824607/suppl/GSM824607_1545_6512_31109_BLEcol0h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824607-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824608">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Ecoli rep2 batch 8 batch 8 1545_6512_31110_BLEcol2h-2</Title>
    <Accession database="GEO">GSM824608</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824608/suppl/GSM824608_1545_6512_31110_BLEcol2h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824608/suppl/GSM824608_1545_6512_31110_BLEcol2h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824608-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824609">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Ecoli rep2 batch 8 batch 8 1545_6512_31111_BLEcol6h-2</Title>
    <Accession database="GEO">GSM824609</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824609/suppl/GSM824609_1545_6512_31111_BLEcol6h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824609/suppl/GSM824609_1545_6512_31111_BLEcol6h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824609-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824610">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Ecoli rep2 batch 8 batch 8 1545_6512_31112_BLEcol12h-2</Title>
    <Accession database="GEO">GSM824610</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824610/suppl/GSM824610_1545_6512_31112_BLEcol12h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824610/suppl/GSM824610_1545_6512_31112_BLEcol12h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824610-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824611">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep2 batch 8 batch 8 1545_6512_31113_BLEcol24h-2</Title>
    <Accession database="GEO">GSM824611</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824611/suppl/GSM824611_1545_6512_31113_BLEcol24h-2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824611/suppl/GSM824611_1545_6512_31113_BLEcol24h-2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824611-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824612">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep3 batch 8 batch 8 1545_6512_31114_AJEcol0h-3</Title>
    <Accession database="GEO">GSM824612</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824612/suppl/GSM824612_1545_6512_31114_AJEcol0h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824612/suppl/GSM824612_1545_6512_31114_AJEcol0h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824612-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824613">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Ecoli rep3 batch 8 batch 8 1545_6512_31115_AJEcol2h-3</Title>
    <Accession database="GEO">GSM824613</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824613/suppl/GSM824613_1545_6512_31115_AJEcol2h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824613/suppl/GSM824613_1545_6512_31115_AJEcol2h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824613-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824614">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Ecoli rep3 batch 8 batch 8 1545_6512_31116_AJEcol6h-3</Title>
    <Accession database="GEO">GSM824614</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824614/suppl/GSM824614_1545_6512_31116_AJEcol6h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824614/suppl/GSM824614_1545_6512_31116_AJEcol6h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824614-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824615">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Ecoli rep3 batch 8 batch 8 1545_6512_31117_AJEcol12h-3</Title>
    <Accession database="GEO">GSM824615</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824615/suppl/GSM824615_1545_6512_31117_AJEcol12h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824615/suppl/GSM824615_1545_6512_31117_AJEcol12h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824615-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824616">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep3 batch 8 batch 8 1545_6512_31118_AJEcol24h-3</Title>
    <Accession database="GEO">GSM824616</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824616/suppl/GSM824616_1545_6512_31118_AJEcol24h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824616/suppl/GSM824616_1545_6512_31118_AJEcol24h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824616-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824617">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep3 batch 8 batch 8 1545_6512_31119_BLEcol0h-3</Title>
    <Accession database="GEO">GSM824617</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824617/suppl/GSM824617_1545_6512_31119_BLEcol0h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824617/suppl/GSM824617_1545_6512_31119_BLEcol0h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824617-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824618">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Ecoli rep3 batch 8 batch 8 1545_6512_31120_BLEcol2h-3</Title>
    <Accession database="GEO">GSM824618</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824618/suppl/GSM824618_1545_6512_31120_BLEcol2h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824618/suppl/GSM824618_1545_6512_31120_BLEcol2h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824618-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824619">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Ecoli rep3 batch 8 batch 8 1545_6512_31121_BLEcol6h-3</Title>
    <Accession database="GEO">GSM824619</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824619/suppl/GSM824619_1545_6512_31121_BLEcol6h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824619/suppl/GSM824619_1545_6512_31121_BLEcol6h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824619-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824620">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Ecoli rep3 batch 8 batch 8 1545_6512_31122_BLEcol12h-3</Title>
    <Accession database="GEO">GSM824620</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824620/suppl/GSM824620_1545_6512_31122_BLEcol12h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824620/suppl/GSM824620_1545_6512_31122_BLEcol12h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824620-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824621">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep3 batch 8 batch 8 1545_6512_31123_BLEcol24h-3</Title>
    <Accession database="GEO">GSM824621</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824621/suppl/GSM824621_1545_6512_31123_BLEcol24h-3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824621/suppl/GSM824621_1545_6512_31123_BLEcol24h-3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824621-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824622">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep4 batch 8 batch 8 1545_6512_31124_AJEcol0h-4</Title>
    <Accession database="GEO">GSM824622</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824622/suppl/GSM824622_1545_6512_31124_AJEcol0h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824622/suppl/GSM824622_1545_6512_31124_AJEcol0h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824622-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824623">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Ecoli rep4 batch 8 batch 8 1545_6512_31125_AJEcol2h-4</Title>
    <Accession database="GEO">GSM824623</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824623/suppl/GSM824623_1545_6512_31125_AJEcol2h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824623/suppl/GSM824623_1545_6512_31125_AJEcol2h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824623-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824624">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Ecoli rep4 batch 8 batch 8 1545_6512_31126_AJEcol6h-4</Title>
    <Accession database="GEO">GSM824624</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824624/suppl/GSM824624_1545_6512_31126_AJEcol6h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824624/suppl/GSM824624_1545_6512_31126_AJEcol6h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824624-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824625">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Ecoli rep4 batch 8 batch 8 1545_6512_31127_AJEcol12h-4</Title>
    <Accession database="GEO">GSM824625</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824625/suppl/GSM824625_1545_6512_31127_AJEcol12h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824625/suppl/GSM824625_1545_6512_31127_AJEcol12h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824625-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824626">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep4 batch 8 batch 8 1545_6512_31128_AJEcol24h-4</Title>
    <Accession database="GEO">GSM824626</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824626/suppl/GSM824626_1545_6512_31128_AJEcol24h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824626/suppl/GSM824626_1545_6512_31128_AJEcol24h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824626-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824627">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep4 batch 8 batch 8 1545_6512_31129_BLEcol0h-4</Title>
    <Accession database="GEO">GSM824627</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824627/suppl/GSM824627_1545_6512_31129_BLEcol0h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824627/suppl/GSM824627_1545_6512_31129_BLEcol0h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824627-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824628">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Ecoli rep4 batch 8 batch 8 1545_6512_31130_BLEcol2h-4</Title>
    <Accession database="GEO">GSM824628</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824628/suppl/GSM824628_1545_6512_31130_BLEcol2h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824628/suppl/GSM824628_1545_6512_31130_BLEcol2h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824628-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824629">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Ecoli rep4 batch 8 batch 8 1545_6512_31131_BLEcol6h-4</Title>
    <Accession database="GEO">GSM824629</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824629/suppl/GSM824629_1545_6512_31131_BLEcol6h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824629/suppl/GSM824629_1545_6512_31131_BLEcol6h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824629-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824630">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Ecoli rep4 batch 8 batch 8 1545_6512_31132_BLEcol12h-4</Title>
    <Accession database="GEO">GSM824630</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824630/suppl/GSM824630_1545_6512_31132_BLEcol12h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824630/suppl/GSM824630_1545_6512_31132_BLEcol12h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824630-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824631">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep4 batch 8 batch 8 1545_6512_31133_BLEcol24h-4</Title>
    <Accession database="GEO">GSM824631</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824631/suppl/GSM824631_1545_6512_31133_BLEcol24h-4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824631/suppl/GSM824631_1545_6512_31133_BLEcol24h-4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824631-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824632">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 0hrs rep5 batch 8 batch 8 1545_6512_31134_AJEcol0h-5</Title>
    <Accession database="GEO">GSM824632</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824632/suppl/GSM824632_1545_6512_31134_AJEcol0h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824632/suppl/GSM824632_1545_6512_31134_AJEcol0h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824632-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824633">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 2hrs Ecoli rep5 batch 8 batch 8 1545_6512_31135_AJEcol2h-5</Title>
    <Accession database="GEO">GSM824633</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824633/suppl/GSM824633_1545_6512_31135_AJEcol2h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824633/suppl/GSM824633_1545_6512_31135_AJEcol2h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824633-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824634">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 6hrs Ecoli rep5 batch 8 batch 8 1545_6512_31136_AJEcol6h-5</Title>
    <Accession database="GEO">GSM824634</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824634/suppl/GSM824634_1545_6512_31136_AJEcol6h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824634/suppl/GSM824634_1545_6512_31136_AJEcol6h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824634-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824635">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 12hrs Ecoli rep5 batch 8 batch 8 1545_6512_31137_AJEcol12h-5</Title>
    <Accession database="GEO">GSM824635</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824635/suppl/GSM824635_1545_6512_31137_AJEcol12h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824635/suppl/GSM824635_1545_6512_31137_AJEcol12h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824635-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824636">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood A/J 24hrs Ecoli rep5 batch 8 batch 8 1545_6512_31138_AJEcol24h-5</Title>
    <Accession database="GEO">GSM824636</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
A/J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824636/suppl/GSM824636_1545_6512_31138_AJEcol24h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824636/suppl/GSM824636_1545_6512_31138_AJEcol24h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824636-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824637">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 0hrs rep5 batch 8 batch 8 1545_6512_31139_BLEcol0h-5</Title>
    <Accession database="GEO">GSM824637</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824637/suppl/GSM824637_1545_6512_31139_BLEcol0h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824637/suppl/GSM824637_1545_6512_31139_BLEcol0h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824637-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824638">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 2hrs Ecoli rep5 batch 8 batch 8 1545_6512_31140_BLEcol2h-5</Title>
    <Accession database="GEO">GSM824638</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood A/J mouse strain blood taken 2 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824638/suppl/GSM824638_1545_6512_31140_BLEcol2h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824638/suppl/GSM824638_1545_6512_31140_BLEcol2h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824638-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824639">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 6hrs Ecoli rep5 batch 8 batch 8 1545_6512_31141_BLEcol6h-5</Title>
    <Accession database="GEO">GSM824639</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 6 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
6
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824639/suppl/GSM824639_1545_6512_31141_BLEcol6h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824639/suppl/GSM824639_1545_6512_31141_BLEcol6h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824639-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824640">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 12hrs Ecoli rep5 batch 8 batch 8 1545_6512_31142_BLEcol12h-5</Title>
    <Accession database="GEO">GSM824640</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 12 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
12
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824640/suppl/GSM824640_1545_6512_31142_BLEcol12h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824640/suppl/GSM824640_1545_6512_31142_BLEcol12h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824640-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824641">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood C57BL/6J 24hrs Ecoli rep5 batch 8 batch 8 1545_6512_31143_BLEcol24h-5</Title>
    <Accession database="GEO">GSM824641</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood C57BL/6J mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
C57BL/6J
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
8
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824641/suppl/GSM824641_1545_6512_31143_BLEcol24h-5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824641/suppl/GSM824641_1545_6512_31143_BLEcol24h-5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824641-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824642">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep1 batch 9 batch 9 1545_4571_25313_control_1</Title>
    <Accession database="GEO">GSM824642</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824642/suppl/GSM824642_1545_4571_25313_control_1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824642/suppl/GSM824642_1545_4571_25313_control_1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824642-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824643">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep2 batch 9 batch 9 1545_4571_25314_control_2</Title>
    <Accession database="GEO">GSM824643</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824643/suppl/GSM824643_1545_4571_25314_control_2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824643/suppl/GSM824643_1545_4571_25314_control_2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824643-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824644">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep1 batch 9 batch 9 1545_4571_25315_Sanger_1</Title>
    <Accession database="GEO">GSM824644</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824644/suppl/GSM824644_1545_4571_25315_Sanger_1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824644/suppl/GSM824644_1545_4571_25315_Sanger_1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824644-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824645">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep2 batch 9 batch 9 1545_4571_25316_Sanger_2</Title>
    <Accession database="GEO">GSM824645</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824645/suppl/GSM824645_1545_4571_25316_Sanger_2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824645/suppl/GSM824645_1545_4571_25316_Sanger_2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824645-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824646">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep1 batch 9 batch 9 1545_4571_25317_USA_1</Title>
    <Accession database="GEO">GSM824646</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824646/suppl/GSM824646_1545_4571_25317_USA_1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824646/suppl/GSM824646_1545_4571_25317_USA_1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824646-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824647">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep2 batch 9 batch 9 1545_4571_25318_USA_2</Title>
    <Accession database="GEO">GSM824647</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824647/suppl/GSM824647_1545_4571_25318_USA_2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824647/suppl/GSM824647_1545_4571_25318_USA_2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824647-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824648">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep1 batch 9 batch 9 1545_4571_25319_Ecoli_1</Title>
    <Accession database="GEO">GSM824648</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
1
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824648/suppl/GSM824648_1545_4571_25319_Ecoli_1_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824648/suppl/GSM824648_1545_4571_25319_Ecoli_1_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824648-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824649">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep2 batch 9 batch 9 1545_4571_25320_Ecoli_2</Title>
    <Accession database="GEO">GSM824649</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
2
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824649/suppl/GSM824649_1545_4571_25320_Ecoli_2_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824649/suppl/GSM824649_1545_4571_25320_Ecoli_2_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824649-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824650">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep3 batch 9 batch 9 1545_4571_25321_control_3</Title>
    <Accession database="GEO">GSM824650</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824650/suppl/GSM824650_1545_4571_25321_control_3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824650/suppl/GSM824650_1545_4571_25321_control_3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824650-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824651">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep4 batch 9 batch 9 1545_4571_25322_control_4</Title>
    <Accession database="GEO">GSM824651</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824651/suppl/GSM824651_1545_4571_25322_control_4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824651/suppl/GSM824651_1545_4571_25322_control_4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824651-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824652">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep3 batch 9 batch 9 1545_4571_25323_Sanger_3</Title>
    <Accession database="GEO">GSM824652</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824652/suppl/GSM824652_1545_4571_25323_Sanger_3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824652/suppl/GSM824652_1545_4571_25323_Sanger_3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824652-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824653">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep4 batch 9 batch 9 1545_4571_25324_Sanger_4</Title>
    <Accession database="GEO">GSM824653</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824653/suppl/GSM824653_1545_4571_25324_Sanger_4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824653/suppl/GSM824653_1545_4571_25324_Sanger_4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824653-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824654">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep3 batch 9 batch 9 1545_4571_25325_USA_3</Title>
    <Accession database="GEO">GSM824654</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824654/suppl/GSM824654_1545_4571_25325_USA_3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824654/suppl/GSM824654_1545_4571_25325_USA_3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824654-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824655">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep4 batch 9 batch 9 1545_4571_25326_USA_4</Title>
    <Accession database="GEO">GSM824655</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824655/suppl/GSM824655_1545_4571_25326_USA_4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824655/suppl/GSM824655_1545_4571_25326_USA_4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824655-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824656">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep3 batch 9 batch 9 1545_4571_25327_Ecoli_3</Title>
    <Accession database="GEO">GSM824656</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
3
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824656/suppl/GSM824656_1545_4571_25327_Ecoli_3_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824656/suppl/GSM824656_1545_4571_25327_Ecoli_3_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824656-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824657">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep4 batch 9 batch 9 1545_4571_25328_Ecoli_4</Title>
    <Accession database="GEO">GSM824657</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
4
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824657/suppl/GSM824657_1545_4571_25328_Ecoli_4_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824657/suppl/GSM824657_1545_4571_25328_Ecoli_4_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824657-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824658">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep5 batch 9 batch 9 1545_4571_25329_control_5</Title>
    <Accession database="GEO">GSM824658</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824658/suppl/GSM824658_1545_4571_25329_control_5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824658/suppl/GSM824658_1545_4571_25329_control_5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824658-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824659">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep6 batch 9 batch 9 1545_4571_25330_control_6</Title>
    <Accession database="GEO">GSM824659</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
6
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824659/suppl/GSM824659_1545_4571_25330_control_6_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824659/suppl/GSM824659_1545_4571_25330_control_6_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824659-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824660">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep5 batch 9 batch 9 1545_4571_25331_Sanger_5</Title>
    <Accession database="GEO">GSM824660</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824660/suppl/GSM824660_1545_4571_25331_Sanger_5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824660/suppl/GSM824660_1545_4571_25331_Sanger_5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824660-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824661">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep6 batch 9 batch 9 1545_4571_25332_Sanger_6</Title>
    <Accession database="GEO">GSM824661</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
6
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824661/suppl/GSM824661_1545_4571_25332_Sanger_6_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824661/suppl/GSM824661_1545_4571_25332_Sanger_6_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824661-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824662">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep5 batch 9 batch 9 1545_4571_25333_USA_5</Title>
    <Accession database="GEO">GSM824662</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824662/suppl/GSM824662_1545_4571_25333_USA_5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824662/suppl/GSM824662_1545_4571_25333_USA_5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824662-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824663">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep6 batch 9 batch 9 1545_4571_25334_USA_6</Title>
    <Accession database="GEO">GSM824663</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
6
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824663/suppl/GSM824663_1545_4571_25334_USA_6_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824663/suppl/GSM824663_1545_4571_25334_USA_6_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824663-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824664">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep5 batch 9 batch 9 1545_4571_25335_Ecoli_5</Title>
    <Accession database="GEO">GSM824664</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
5
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824664/suppl/GSM824664_1545_4571_25335_Ecoli_5_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824664/suppl/GSM824664_1545_4571_25335_Ecoli_5_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824664-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824665">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep6 batch 9 batch 9 1545_4571_25336_Ecoli_6</Title>
    <Accession database="GEO">GSM824665</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
6
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824665/suppl/GSM824665_1545_4571_25336_Ecoli_6_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824665/suppl/GSM824665_1545_4571_25336_Ecoli_6_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824665-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824666">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep7 batch 9 batch 9 1545_4571_25337_control_7</Title>
    <Accession database="GEO">GSM824666</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
7
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824666/suppl/GSM824666_1545_4571_25337_control_7_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824666/suppl/GSM824666_1545_4571_25337_control_7_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824666-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824667">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep8 batch 9 batch 9 1545_4571_25338_control_8</Title>
    <Accession database="GEO">GSM824667</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
8
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824667/suppl/GSM824667_1545_4571_25338_control_8_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824667/suppl/GSM824667_1545_4571_25338_control_8_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824667-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824668">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep7 batch 9 batch 9 1545_4571_25339_Sanger_7</Title>
    <Accession database="GEO">GSM824668</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
7
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824668/suppl/GSM824668_1545_4571_25339_Sanger_7_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824668/suppl/GSM824668_1545_4571_25339_Sanger_7_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824668-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824669">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep8 batch 9 batch 9 1545_4571_25340_Sanger_8</Title>
    <Accession database="GEO">GSM824669</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
8
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824669/suppl/GSM824669_1545_4571_25340_Sanger_8_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824669/suppl/GSM824669_1545_4571_25340_Sanger_8_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824669-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824670">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep7 batch 9 batch 9 1545_4571_25341_USA_7</Title>
    <Accession database="GEO">GSM824670</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
7
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824670/suppl/GSM824670_1545_4571_25341_USA_7_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824670/suppl/GSM824670_1545_4571_25341_USA_7_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824670-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824671">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep8 batch 9 batch 9 1545_4571_25342_USA_8</Title>
    <Accession database="GEO">GSM824671</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
8
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824671/suppl/GSM824671_1545_4571_25342_USA_8_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824671/suppl/GSM824671_1545_4571_25342_USA_8_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824671-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824672">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep7 batch 9 batch 9 1545_4571_25343_Ecoli_7</Title>
    <Accession database="GEO">GSM824672</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
7
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824672/suppl/GSM824672_1545_4571_25343_Ecoli_7_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824672/suppl/GSM824672_1545_4571_25343_Ecoli_7_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824672-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824673">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep8 batch 9 batch 9 1545_4571_25344_Ecoli_8</Title>
    <Accession database="GEO">GSM824673</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
8
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824673/suppl/GSM824673_1545_4571_25344_Ecoli_8_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824673/suppl/GSM824673_1545_4571_25344_Ecoli_8_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824673-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824674">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep9 batch 9 batch 9 1545_4571_25345_control_9</Title>
    <Accession database="GEO">GSM824674</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
9
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824674/suppl/GSM824674_1545_4571_25345_control_9_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824674/suppl/GSM824674_1545_4571_25345_control_9_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824674-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824675">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 0hrs rep10 batch 9 batch 9 1545_4571_25346_control_10</Title>
    <Accession database="GEO">GSM824675</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain NOT infected</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="bacterial strain">
-
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
-
      </Characteristics>
      <Characteristics tag="inoculum route">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
-
      </Characteristics>
      <Characteristics tag="time after infection (h)">
0
      </Characteristics>
      <Characteristics tag="replicate number">
10
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824675/suppl/GSM824675_1545_4571_25346_control_10_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824675/suppl/GSM824675_1545_4571_25346_control_10_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824675-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824676">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep9 batch 9 batch 9 1545_4571_25347_Sanger_9</Title>
    <Accession database="GEO">GSM824676</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
9
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824676/suppl/GSM824676_1545_4571_25347_Sanger_9_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824676/suppl/GSM824676_1545_4571_25347_Sanger_9_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824676-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824677">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs Sanger rep10 batch 9 batch 9 1545_4571_25348_Sanger_10</Title>
    <Accession database="GEO">GSM824677</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus Sanger476</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
Sanger476
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
10
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824677/suppl/GSM824677_1545_4571_25348_Sanger_10_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824677/suppl/GSM824677_1545_4571_25348_Sanger_10_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824677-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824678">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep9 batch 9 batch 9 1545_4571_25349_USA_9</Title>
    <Accession database="GEO">GSM824678</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
9
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824678/suppl/GSM824678_1545_4571_25349_USA_9_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824678/suppl/GSM824678_1545_4571_25349_USA_9_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824678-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824679">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 2hrs USA300 rep10 batch 9 batch 9 1545_4571_25350_USA_10</Title>
    <Accession database="GEO">GSM824679</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 2 hours after infection with S. aureus USA300</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="bacterial strain">
USA300
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
1.00E+07
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
2
      </Characteristics>
      <Characteristics tag="replicate number">
10
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824679/suppl/GSM824679_1545_4571_25350_USA_10_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824679/suppl/GSM824679_1545_4571_25350_USA_10_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824679-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824680">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep9 batch 9 batch 9 1545_4571_25351_Ecoli_9</Title>
    <Accession database="GEO">GSM824680</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
9
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824680/suppl/GSM824680_1545_4571_25351_Ecoli_9_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824680/suppl/GSM824680_1545_4571_25351_Ecoli_9_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824680-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824681">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood CD1 24hrs Ecoli rep10 batch 9 batch 9 1545_4571_25352_Ecoli_10</Title>
    <Accession database="GEO">GSM824681</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood CD1 mouse strain blood taken 24 hours after infection with E. coli</Source>
      <Organism taxid="10090">Mus musculus</Organism>
      <Characteristics tag="host strain">
CD1
      </Characteristics>
      <Characteristics tag="host gender">
male
      </Characteristics>
      <Characteristics tag="host age (yr)">
0.50-0.66
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia  coli
      </Characteristics>
      <Characteristics tag="bacterial strain">
O18:K1:H7
      </Characteristics>
      <Characteristics tag="pathogen   dosage cfu/g">
6.00E+04
      </Characteristics>
      <Characteristics tag="inoculum route">
peritoneum
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="infection status">
infected
      </Characteristics>
      <Characteristics tag="time after infection (h)">
24
      </Characteristics>
      <Characteristics tag="replicate number">
10
      </Characteristics>
      <Characteristics tag="experimental batch">
9
      </Characteristics>
      <Treatment-Protocol>
To mimic the natural course of S. aureus infection in humans, which typically arises from a primary focus of infection and disseminates to other sites, we employed an intraperitoneal (i.p.) route of infection in our animal model.
      </Treatment-Protocol>
      <Growth-Protocol>
One methicillin-susceptible S. aureus strain (Sanger 476) and three methicillin-resistant S. aureus strains (USA100, USA300, and MW2) were used.  Overnight S. aureus cultures were inoculated into fresh tryptic soy broth and incubated aerobically at 30°C to log-phase growth (optical density 600nm of ~1.0) (Rice et al., 2003).  Cells were harvested by centrifugation, rinsed, and resuspended in phosphate-buffered saline (PBS).  E. coli O18:K1:H7 was grown at 30°C overnight in Luria Bertani broth (Miller et al., 1972).  Cultures were then diluted with fresh medium and grown for an additional 1 to 2 hours.  Upon reaching log phase, cells were harvested by centrifugation, washed, and resuspended in PBS.
      </Growth-Protocol>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from mouse blood using the Mouse RiboPure Blood RNA kit (Ambion, Austin, TX) according to the manufacturer’s instructions. Globin mRNA was removed from whole blood RNA using the Globinclear kit (Ambion, Austin, TX). All samples passed the quality criteria of the Agilent Bioanalyzer and were used for microarray analysis. Since the total RNA yield of many samples was low, one round of linear amplification was performed for all samples using the MessageAmp Premier kit (Ambion, Austin, TX).
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.5 ug total RNA (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Biotin-labeled cDNA was hybridized to the arrays for 16 hours at 45°C according to the manufacturer’s instruction. Arrays were then washed and labeled with streptavidinphycoerythrin (strep-PE), and the signal was amplified using biotinylated antistreptavidin followed by another round of staining with strep-PE. These steps were performed on the Affymetrix fluidics station according to the recommended protocol.
    </Hybridization-Protocol>
    <Scan-Protocol>
Amplification and microarray hybridization were performed at the Duke University Microarray Core. Labeled gene chips were scanned using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
    </Scan-Protocol>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software. Microarray data was analyzed in two steps following the analysis strategy previously outlined and utilized (Zaas et al., 2010). First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype (Carvalho et al., 2008; Wang et al., 2007). Second, factors were then used to build a probit regression with variable selection model (Hans et al., 2007) trained to identify S. aureus infection.
    </Data-Processing>
    <Platform-Ref ref="GPL1261" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824681/suppl/GSM824681_1545_4571_25352_Ecoli_10_Mouse430+2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824681/suppl/GSM824681_1545_4571_25352_Ecoli_10_Mouse430+2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="45101">
GSM824681-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824707">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [CS101-D00649.CEL]</Title>
    <Accession database="GEO">GSM824707</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
43
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824707/suppl/GSM824707_2034_106101_H133A2_28013_CS101-D00649.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824707/suppl/GSM824707_2034_106101_H133A2_28013_CS101-D00649.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824707-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824708">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D887.2.CEL]</Title>
    <Accession database="GEO">GSM824708</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
49
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824708/suppl/GSM824708_2034_106107_H133A2_28019_D887.2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824708/suppl/GSM824708_2034_106107_H133A2_28019_D887.2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824708-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824709">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [CSD5036.CEL]</Title>
    <Accession database="GEO">GSM824709</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
44
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824709/suppl/GSM824709_2034_106130_H133A2_28032_CSD5036.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824709/suppl/GSM824709_2034_106130_H133A2_28032_CSD5036.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824709-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824710">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [CSD2575.CEL]</Title>
    <Accession database="GEO">GSM824710</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
70
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824710/suppl/GSM824710_2034_107257_H133A2_27988_CSD2575.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824710/suppl/GSM824710_2034_107257_H133A2_27988_CSD2575.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824710-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824711">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D2341.CEL]</Title>
    <Accession database="GEO">GSM824711</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
40
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824711/suppl/GSM824711_2287_105863_H133A2_28154_D2341.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824711/suppl/GSM824711_2287_105863_H133A2_28154_D2341.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824711-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824712">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D2173.CEL]</Title>
    <Accession database="GEO">GSM824712</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
91
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824712/suppl/GSM824712_2287_105868_H133A2_28149_D2173.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824712/suppl/GSM824712_2287_105868_H133A2_28149_D2173.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824712-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824713">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D2033.CEL]</Title>
    <Accession database="GEO">GSM824713</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824713/suppl/GSM824713_2287_105870_H133A2_28147_D2033.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824713/suppl/GSM824713_2287_105870_H133A2_28147_D2033.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824713-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824714">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D5294.CEL]</Title>
    <Accession database="GEO">GSM824714</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
62
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824714/suppl/GSM824714_2287_105872_H133A2_28156_D5294.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824714/suppl/GSM824714_2287_105872_H133A2_28156_D5294.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824714-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824715">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D5459.CEL]</Title>
    <Accession database="GEO">GSM824715</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
70
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824715/suppl/GSM824715_2287_105874_H133A2_28158_D5459.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824715/suppl/GSM824715_2287_105874_H133A2_28158_D5459.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824715-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824716">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [D8414.CEL]</Title>
    <Accession database="GEO">GSM824716</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
32
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824716/suppl/GSM824716_2287_105881_H133A2_28165_D8414.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824716/suppl/GSM824716_2287_105881_H133A2_28165_D8414.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824716-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824717">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [CS564-D8671.CEL]</Title>
    <Accession database="GEO">GSM824717</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
54
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824717/suppl/GSM824717_2034_106555_H133A2_28011_CS564-D8671.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824717/suppl/GSM824717_2034_106555_H133A2_28011_CS564-D8671.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824717-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824718">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [CS593-D9156.CEL]</Title>
    <Accession database="GEO">GSM824718</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
74
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824718/suppl/GSM824718_2034_106556_H133A2_28012_CS593-D9156.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824718/suppl/GSM824718_2034_106556_H133A2_28012_CS593-D9156.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824718-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824719">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [F00210.CEL]</Title>
    <Accession database="GEO">GSM824719</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
79
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Lung
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824719/suppl/GSM824719_2034_94500_H133A2_23562_F00210.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824719/suppl/GSM824719_2034_94500_H133A2_23562_F00210.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824719-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824720">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [V355.CEL]</Title>
    <Accession database="GEO">GSM824720</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
41
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824720/suppl/GSM824720_2287_105855_H133A2_28337_V355.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824720/suppl/GSM824720_2287_105855_H133A2_28337_V355.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824720-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824721">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CSD4620.CEL]</Title>
    <Accession database="GEO">GSM824721</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
82
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Cardiac-Endocarditis
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824721/suppl/GSM824721_2034_106551_H133A2_27990_CSD4620.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824721/suppl/GSM824721_2034_106551_H133A2_27990_CSD4620.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824721-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824722">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CS253-D3500.CEL]</Title>
    <Accession database="GEO">GSM824722</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
70
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824722/suppl/GSM824722_2034_94193_H133A2_23792_CS253-D3500.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824722/suppl/GSM824722_2034_94193_H133A2_23792_CS253-D3500.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824722-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824723">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CSD4396.CEL]</Title>
    <Accession database="GEO">GSM824723</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
41
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824723/suppl/GSM824723_2034_106075_H133A2_27992_CSD4396.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824723/suppl/GSM824723_2034_106075_H133A2_27992_CSD4396.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824723-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824724">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CSD4470.CEL]</Title>
    <Accession database="GEO">GSM824724</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
81
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824724/suppl/GSM824724_2034_107258_H133A2_27989_CSD4470.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824724/suppl/GSM824724_2034_107258_H133A2_27989_CSD4470.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824724-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824725">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CS439-D5657.CEL]</Title>
    <Accession database="GEO">GSM824725</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
81
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824725/suppl/GSM824725_2034_97547_H133A2_23809_CS439-D5657.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824725/suppl/GSM824725_2034_97547_H133A2_23809_CS439-D5657.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824725-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824726">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CS445-D5781.CEL]</Title>
    <Accession database="GEO">GSM824726</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
55
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824726/suppl/GSM824726_2034_97548_H133A2_23810_CS445-D5781.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824726/suppl/GSM824726_2034_97548_H133A2_23810_CS445-D5781.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824726-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824727">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CS453-D5936.CEL]</Title>
    <Accession database="GEO">GSM824727</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
69
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824727/suppl/GSM824727_2034_97550_H133A2_23812_CS453-D5936.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824727/suppl/GSM824727_2034_97550_H133A2_23812_CS453-D5936.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824727-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824728">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CS475-D6291.CEL]</Title>
    <Accession database="GEO">GSM824728</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
44
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824728/suppl/GSM824728_2034_97551_H133A2_23813_CS475-D6291.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824728/suppl/GSM824728_2034_97551_H133A2_23813_CS475-D6291.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824728-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824729">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [F00611.CEL]</Title>
    <Accession database="GEO">GSM824729</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
51
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824729/suppl/GSM824729_2034_94495_H133A2_23557_F00611.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824729/suppl/GSM824729_2034_94495_H133A2_23557_F00611.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824729-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824730">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [F00520.CEL]</Title>
    <Accession database="GEO">GSM824730</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
47
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824730/suppl/GSM824730_2034_94496_H133A2_23558_F00520.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824730/suppl/GSM824730_2034_94496_H133A2_23558_F00520.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824730-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824731">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [F00506.CEL]</Title>
    <Accession database="GEO">GSM824731</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
36
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Cardiac
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824731/suppl/GSM824731_2034_94497_H133A2_23559_F00506.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824731/suppl/GSM824731_2034_94497_H133A2_23559_F00506.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824731-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824732">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [002-0159PAXGENEENR.CEL]</Title>
    <Accession database="GEO">GSM824732</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
54
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824732/suppl/GSM824732_2034_97401_H133A2_24532_002-0159PAXGENEENR.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824732/suppl/GSM824732_2034_97401_H133A2_24532_002-0159PAXGENEENR.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824732-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824733">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [H785.CEL]</Title>
    <Accession database="GEO">GSM824733</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
55
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824733/suppl/GSM824733_2034_94509_H133A2_23571_H785.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824733/suppl/GSM824733_2034_94509_H133A2_23571_H785.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824733-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824734">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [H638.CEL]</Title>
    <Accession database="GEO">GSM824734</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
42
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Unknown
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824734/suppl/GSM824734_2034_94511_H133A2_23573_H638.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824734/suppl/GSM824734_2034_94511_H133A2_23573_H638.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824734-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824735">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [002-0216ENRPAXGENE1.CEL]</Title>
    <Accession database="GEO">GSM824735</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
52
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824735/suppl/GSM824735_2034_94514_H133A2_23576_002-0216ENRPAXGENE1.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824735/suppl/GSM824735_2034_94514_H133A2_23576_002-0216ENRPAXGENE1.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824735-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824736">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [H3229.CEL]</Title>
    <Accession database="GEO">GSM824736</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
55
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824736/suppl/GSM824736_2034_95963_H133A2_24190_H3229.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824736/suppl/GSM824736_2034_95963_H133A2_24190_H3229.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824736-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824737">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [H3722.CEL]</Title>
    <Accession database="GEO">GSM824737</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
52
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824737/suppl/GSM824737_2034_95992_H133A2_24219_H3722.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824737/suppl/GSM824737_2034_95992_H133A2_24219_H3722.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824737-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824738">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [H4129.CEL]</Title>
    <Accession database="GEO">GSM824738</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Unknown
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
51
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Lung
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824738/suppl/GSM824738_2034_95994_H133A2_24221_H4129.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824738/suppl/GSM824738_2034_95994_H133A2_24221_H4129.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824738-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824739">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [002-040424HRSPAXGENE.CEL]</Title>
    <Accession database="GEO">GSM824739</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
40
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824739/suppl/GSM824739_2034_96001_H133A2_24228_002-040424HRSPAXGENE.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824739/suppl/GSM824739_2034_96001_H133A2_24228_002-040424HRSPAXGENE.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824739-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824740">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [V943.CEL]</Title>
    <Accession database="GEO">GSM824740</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
60
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824740/suppl/GSM824740_2034_93963_H133A2_23530_V943.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824740/suppl/GSM824740_2034_93963_H133A2_23530_V943.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824740-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824741">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [V674.CEL]</Title>
    <Accession database="GEO">GSM824741</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
59
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824741/suppl/GSM824741_2287_105860_H133A2_28338_V674.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824741/suppl/GSM824741_2287_105860_H133A2_28338_V674.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824741-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824742">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [V738.CEL]</Title>
    <Accession database="GEO">GSM824742</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
58
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824742/suppl/GSM824742_2034_93965_H133A2_23532_V738.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824742/suppl/GSM824742_2034_93965_H133A2_23532_V738.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824742-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824743">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [V710.CEL]</Title>
    <Accession database="GEO">GSM824743</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
77
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824743/suppl/GSM824743_2034_93966_H133A2_23533_V710.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824743/suppl/GSM824743_2034_93966_H133A2_23533_V710.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824743-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824744">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [002-0161PAXGENEENR.CEL]</Title>
    <Accession database="GEO">GSM824744</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
91
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Bone
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824744/suppl/GSM824744_2034_97402_H133A2_24533_002-0161PAXGENEENR.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824744/suppl/GSM824744_2034_97402_H133A2_24533_002-0161PAXGENEENR.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824744-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824745">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [H2534.CEL]</Title>
    <Accession database="GEO">GSM824745</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
white
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
75
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824745/suppl/GSM824745_2034_95984_H133A2_24211_H2534.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824745/suppl/GSM824745_2034_95984_H133A2_24211_H2534.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824745-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824746">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [002-0415ENRPAXGENE.CEL]</Title>
    <Accession database="GEO">GSM824746</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
58
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
vascular catheter
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824746/suppl/GSM824746_2034_96003_H133A2_24230_002-0415ENRPAXGENE.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824746/suppl/GSM824746_2034_96003_H133A2_24230_002-0415ENRPAXGENE.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824746-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824747">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00413.CEL]</Title>
    <Accession database="GEO">GSM824747</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
27
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824747/suppl/GSM824747_2287_105960_H133A2_28167_DU09-01S00413.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824747/suppl/GSM824747_2287_105960_H133A2_28167_DU09-01S00413.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824747-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824748">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00446.CEL]</Title>
    <Accession database="GEO">GSM824748</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824748/suppl/GSM824748_2287_105954_H133A2_28172_DU09-01S00446.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824748/suppl/GSM824748_2287_105954_H133A2_28172_DU09-01S00446.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824748-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824749">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00407.CEL]</Title>
    <Accession database="GEO">GSM824749</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
29
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824749/suppl/GSM824749_2287_105959_H133A2_28166_DU09-01S00407.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824749/suppl/GSM824749_2287_105959_H133A2_28166_DU09-01S00407.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824749-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824750">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00421.CEL]</Title>
    <Accession database="GEO">GSM824750</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824750/suppl/GSM824750_2287_105955_H133A2_28169_DU09-01S00421.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824750/suppl/GSM824750_2287_105955_H133A2_28169_DU09-01S00421.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824750-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824751">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00415.CEL]</Title>
    <Accession database="GEO">GSM824751</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Asian
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
30
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824751/suppl/GSM824751_2287_105956_H133A2_28168_DU09-01S00415.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824751/suppl/GSM824751_2287_105956_H133A2_28168_DU09-01S00415.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824751-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824752">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00427.CEL]</Title>
    <Accession database="GEO">GSM824752</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824752/suppl/GSM824752_2287_105957_H133A2_28170_DU09-01S00427.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824752/suppl/GSM824752_2287_105957_H133A2_28170_DU09-01S00427.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824752-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824753">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00473.CEL]</Title>
    <Accession database="GEO">GSM824753</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
unknown
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824753/suppl/GSM824753_2287_105953_H133A2_28173_DU09-01S00473.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824753/suppl/GSM824753_2287_105953_H133A2_28173_DU09-01S00473.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824753-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824754">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00433.CEL]</Title>
    <Accession database="GEO">GSM824754</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Asian
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824754/suppl/GSM824754_2287_105958_H133A2_28171_DU09-01S00433.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824754/suppl/GSM824754_2287_105958_H133A2_28171_DU09-01S00433.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824754-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824755">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00785.CEL]</Title>
    <Accession database="GEO">GSM824755</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Asian
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
23
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824755/suppl/GSM824755_2287_105969_H133A2_28189_DU09-01S00785.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824755/suppl/GSM824755_2287_105969_H133A2_28189_DU09-01S00785.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824755-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824756">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00633.CEL]</Title>
    <Accession database="GEO">GSM824756</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
50
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824756/suppl/GSM824756_2287_105938_H133A2_28181_DU09-01S00633.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824756/suppl/GSM824756_2287_105938_H133A2_28181_DU09-01S00633.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824756-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824757">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00779.CEL]</Title>
    <Accession database="GEO">GSM824757</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
23
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824757/suppl/GSM824757_2287_105970_H133A2_28188_DU09-01S00779.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824757/suppl/GSM824757_2287_105970_H133A2_28188_DU09-01S00779.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824757-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824758">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00928.CEL]</Title>
    <Accession database="GEO">GSM824758</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824758/suppl/GSM824758_2287_105961_H133A2_28196_DU09-01S00928.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824758/suppl/GSM824758_2287_105961_H133A2_28196_DU09-01S00928.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824758-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824759">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00538.CEL]</Title>
    <Accession database="GEO">GSM824759</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
44
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824759/suppl/GSM824759_2287_105943_H133A2_28174_DU09-01S00538.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824759/suppl/GSM824759_2287_105943_H133A2_28174_DU09-01S00538.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824759-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824760">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00563.CEL]</Title>
    <Accession database="GEO">GSM824760</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824760/suppl/GSM824760_2287_105942_H133A2_28175_DU09-01S00563.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824760/suppl/GSM824760_2287_105942_H133A2_28175_DU09-01S00563.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824760-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824761">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00691.CEL]</Title>
    <Accession database="GEO">GSM824761</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
28
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824761/suppl/GSM824761_2287_105972_H133A2_28185_DU09-01S00691.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824761/suppl/GSM824761_2287_105972_H133A2_28185_DU09-01S00691.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824761-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824762">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00971.CEL]</Title>
    <Accession database="GEO">GSM824762</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824762/suppl/GSM824762_2287_105952_H133A2_28198_DU09-01S00971.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824762/suppl/GSM824762_2287_105952_H133A2_28198_DU09-01S00971.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824762-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824763">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00671.CEL]</Title>
    <Accession database="GEO">GSM824763</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Asian
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
30
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824763/suppl/GSM824763_2287_105975_H133A2_28184_DU09-01S00671.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824763/suppl/GSM824763_2287_105975_H133A2_28184_DU09-01S00671.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824763-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824764">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01164.CEL]</Title>
    <Accession database="GEO">GSM824764</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824764/suppl/GSM824764_2287_105983_H133A2_28209_DU09-01S01164.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824764/suppl/GSM824764_2287_105983_H133A2_28209_DU09-01S01164.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824764-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824765">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00946.CEL]</Title>
    <Accession database="GEO">GSM824765</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824765/suppl/GSM824765_2287_105962_H133A2_28197_DU09-01S00946.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824765/suppl/GSM824765_2287_105962_H133A2_28197_DU09-01S00946.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824765-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824766">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00841.CEL]</Title>
    <Accession database="GEO">GSM824766</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824766/suppl/GSM824766_2287_105965_H133A2_28194_DU09-01S00841.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824766/suppl/GSM824766_2287_105965_H133A2_28194_DU09-01S00841.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824766-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824767">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01065.CEL]</Title>
    <Accession database="GEO">GSM824767</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824767/suppl/GSM824767_2287_105947_H133A2_28204_DU09-01S01065.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824767/suppl/GSM824767_2287_105947_H133A2_28204_DU09-01S01065.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824767-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824768">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01011.CEL]</Title>
    <Accession database="GEO">GSM824768</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Asian
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824768/suppl/GSM824768_2287_105951_H133A2_28201_DU09-01S01011.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824768/suppl/GSM824768_2287_105951_H133A2_28201_DU09-01S01011.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824768-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824769">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01046.CEL]</Title>
    <Accession database="GEO">GSM824769</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824769/suppl/GSM824769_2287_105948_H133A2_28203_DU09-01S01046.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824769/suppl/GSM824769_2287_105948_H133A2_28203_DU09-01S01046.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824769-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824770">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00627.CEL]</Title>
    <Accession database="GEO">GSM824770</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
43
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824770/suppl/GSM824770_2287_105937_H133A2_28180_DU09-01S00627.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824770/suppl/GSM824770_2287_105937_H133A2_28180_DU09-01S00627.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824770-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824771">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00835.CEL]</Title>
    <Accession database="GEO">GSM824771</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824771/suppl/GSM824771_2287_105964_H133A2_28193_DU09-01S00835.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824771/suppl/GSM824771_2287_105964_H133A2_28193_DU09-01S00835.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824771-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824772">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00588.CEL]</Title>
    <Accession database="GEO">GSM824772</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
59
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824772/suppl/GSM824772_2287_105939_H133A2_28177DU09-01S00588.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824772/suppl/GSM824772_2287_105939_H133A2_28177DU09-01S00588.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824772-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824773">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00601.CEL]</Title>
    <Accession database="GEO">GSM824773</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824773/suppl/GSM824773_2287_105940_H133A2_28178_DU09-01S00601.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824773/suppl/GSM824773_2287_105940_H133A2_28178_DU09-01S00601.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824773-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824774">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00652.CEL]</Title>
    <Accession database="GEO">GSM824774</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824774/suppl/GSM824774_2287_105935_H133A2_28182_DU09-01S00652.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824774/suppl/GSM824774_2287_105935_H133A2_28182_DU09-01S00652.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824774-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824775">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00798.CEL]</Title>
    <Accession database="GEO">GSM824775</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824775/suppl/GSM824775_2287_105966_H133A2_28190_DU09-01S00798.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824775/suppl/GSM824775_2287_105966_H133A2_28190_DU09-01S00798.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824775-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824776">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00822.CEL]</Title>
    <Accession database="GEO">GSM824776</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824776/suppl/GSM824776_2287_105967_H133A2_28192_DU09-01S00822.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824776/suppl/GSM824776_2287_105967_H133A2_28192_DU09-01S00822.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824776-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824777">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00810.CEL]</Title>
    <Accession database="GEO">GSM824777</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824777/suppl/GSM824777_2287_105968_H133A2_28191_DU09-01S00810.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824777/suppl/GSM824777_2287_105968_H133A2_28191_DU09-01S00810.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824777-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824778">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01017.CEL]</Title>
    <Accession database="GEO">GSM824778</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824778/suppl/GSM824778_2287_105949_H133A2_28202_DU09-01S01017.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824778/suppl/GSM824778_2287_105949_H133A2_28202_DU09-01S01017.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824778-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824779">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00995.CEL]</Title>
    <Accession database="GEO">GSM824779</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Unknown
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824779/suppl/GSM824779_2287_105984_H133A2_28199_DU09-01S00995.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824779/suppl/GSM824779_2287_105984_H133A2_28199_DU09-01S00995.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824779-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824780">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S00735.CEL]</Title>
    <Accession database="GEO">GSM824780</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
53
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824780/suppl/GSM824780_2287_105971_H133A2_28187_DU09-01S00735.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824780/suppl/GSM824780_2287_105971_H133A2_28187_DU09-01S00735.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824780-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824781">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01091.CEL]</Title>
    <Accession database="GEO">GSM824781</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
45
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824781/suppl/GSM824781_2287_105946_H133A2_28205_DU09-01S01091.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824781/suppl/GSM824781_2287_105946_H133A2_28205_DU09-01S01091.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824781-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824782">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01235.CEL]</Title>
    <Accession database="GEO">GSM824782</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
23
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824782/suppl/GSM824782_2287_105979_H133A2_28211_DU09-01S01235.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824782/suppl/GSM824782_2287_105979_H133A2_28211_DU09-01S01235.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824782-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824783">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01128.CEL]</Title>
    <Accession database="GEO">GSM824783</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
26
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824783/suppl/GSM824783_2287_105985_H133A2_28208_DU09-01S01128.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824783/suppl/GSM824783_2287_105985_H133A2_28208_DU09-01S01128.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824783-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824784">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01122.CEL]</Title>
    <Accession database="GEO">GSM824784</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
27
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824784/suppl/GSM824784_2287_105945_H133A2_28207_DU09-01S01122.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824784/suppl/GSM824784_2287_105945_H133A2_28207_DU09-01S01122.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824784-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824785">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01183.CEL]</Title>
    <Accession database="GEO">GSM824785</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Asian
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
43
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824785/suppl/GSM824785_2287_105982_H133A2_28210_DU09-01S01183.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824785/suppl/GSM824785_2287_105982_H133A2_28210_DU09-01S01183.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824785-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824786">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01241.CEL]</Title>
    <Accession database="GEO">GSM824786</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
32
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824786/suppl/GSM824786_2287_105980_H133A2_28212_DU09-01S01241.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824786/suppl/GSM824786_2287_105980_H133A2_28212_DU09-01S01241.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824786-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824787">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01246.CEL]</Title>
    <Accession database="GEO">GSM824787</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
unknown
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
25
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824787/suppl/GSM824787_2287_105981_H133A2_28213_DU09-01S01246.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824787/suppl/GSM824787_2287_105981_H133A2_28213_DU09-01S01246.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824787-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824788">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01276.CEL]</Title>
    <Accession database="GEO">GSM824788</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
43
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824788/suppl/GSM824788_2287_105978_H133A2_28216_DU09-01S01276.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824788/suppl/GSM824788_2287_105978_H133A2_28216_DU09-01S01276.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824788-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM824790">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood healthy control [DU09-01S01271.CEL]</Title>
    <Accession database="GEO">GSM824790</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood human NOT infected</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
42
      </Characteristics>
      <Characteristics tag="pathogen">
-
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
-
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824790/suppl/GSM824790_2287_105977_H133A2_28215_DU09-01S01271.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM824nnn/GSM824790/suppl/GSM824790_2287_105977_H133A2_28215_DU09-01S01271.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM824790-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932374">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [F02098]</Title>
    <Accession database="GEO">GSM932374</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
52
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus and Streptococcus pneumoniae
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
lung
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932374/suppl/GSM932374_2034_97390_H133A2_24521_F02098.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932374/suppl/GSM932374_2034_97390_H133A2_24521_F02098.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932374-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932375">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [F01541]</Title>
    <Accession database="GEO">GSM932375</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
38
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
cardiac
      </Characteristics>
      <Characteristics tag="experimental batch">
2034
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932375/suppl/GSM932375_2034_97393_H133A2_24524_F01541.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932375/suppl/GSM932375_2034_97393_H133A2_24524_F01541.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932375-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932376">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [CS127-D00256]</Title>
    <Accession database="GEO">GSM932376</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
24
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
urinary tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2287
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932376/suppl/GSM932376_2287_106523_H133A2_28125_CS127-D00256.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932376/suppl/GSM932376_2287_106523_H133A2_28125_CS127-D00256.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932376-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932377">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [DU09-03S92423]</Title>
    <Accession database="GEO">GSM932377</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
74
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin or Skin Structure
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932377/suppl/GSM932377_2739_136828_HG-U133A_2_DU09-03S92423_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932377/suppl/GSM932377_2739_136828_HG-U133A_2_DU09-03S92423_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932377-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932378">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [DU09-03S93303]</Title>
    <Accession database="GEO">GSM932378</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
70
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Skin or Skin Structure
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932378/suppl/GSM932378_2739_136830_HG-U133A_2_DU09-03S93303_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932378/suppl/GSM932378_2739_136830_HG-U133A_2_DU09-03S93303_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932378-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932379">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with S. aureus bacteremia [DU09-03S95905]</Title>
    <Accession database="GEO">GSM932379</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with S. aureus bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
61
      </Characteristics>
      <Characteristics tag="pathogen">
Staphylococcus aureus
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
CNS
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932379/suppl/GSM932379_2739_136834_HG-U133A_2_DU09-03S95905_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932379/suppl/GSM932379_2739_136834_HG-U133A_2_DU09-03S95905_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932379-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932380">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [DU09-03S96738]</Title>
    <Accession database="GEO">GSM932380</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Male
      </Characteristics>
      <Characteristics tag="host age (yr)">
65
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary Tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932380/suppl/GSM932380_2739_136838_HG-U133A_2_DU09-03S96738_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932380/suppl/GSM932380_2739_136838_HG-U133A_2_DU09-03S96738_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932380-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932381">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [DU09-03S07915]</Title>
    <Accession database="GEO">GSM932381</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
63
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary Tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932381/suppl/GSM932381_2739_136840_HG-U133A_2_DU09-03S07915_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932381/suppl/GSM932381_2739_136840_HG-U133A_2_DU09-03S07915_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932381-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932382">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [DU10-01S02093]</Title>
    <Accession database="GEO">GSM932382</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
81
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary Tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932382/suppl/GSM932382_2739_136844_HG-U133A_2_DU10-01S02093_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932382/suppl/GSM932382_2739_136844_HG-U133A_2_DU10-01S02093_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932382-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932383">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [DU10-01S03145]</Title>
    <Accession database="GEO">GSM932383</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
Black
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
69
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary Tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932383/suppl/GSM932383_2739_136850_HG-U133A_2_DU10-01S03145_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932383/suppl/GSM932383_2739_136850_HG-U133A_2_DU10-01S03145_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932383-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM932384">
    <Status database="GEO">
      <Submission-Date>2012-05-17</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2013-01-11</Last-Update-Date>
    </Status>
    <Title>blood patient with E. coli bacteremia [DU10-01S06732]</Title>
    <Accession database="GEO">GSM932384</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>blood patient with E. coli bacteremia prior antibiotic treatment (Emergency Department)</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="ethnicity">
White
      </Characteristics>
      <Characteristics tag="host gender">
Female
      </Characteristics>
      <Characteristics tag="host age (yr)">
55
      </Characteristics>
      <Characteristics tag="pathogen">
Escherichia coli
      </Characteristics>
      <Characteristics tag="anatomic site of infection">
Urinary Tract
      </Characteristics>
      <Characteristics tag="experimental batch">
2739
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Total RNA was extracted from human blood using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) following the manufacturer’s recommended protocol including DNase treatment.  Following isolation, RNA quantity was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). A set of four peptide nuleic acid (PNA) oligomers (Applied Biosystems, Foster City, CA) with sequences complimentary to globin mRNA were added to 2.5 ug of total RNA to reduce globin RNA transcription, then converted into cDNA using Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that contains T7 promoter sequences (GenSet).   After first strand synthesis, residual RNA was degraded by the addition of RNaseH and a double-stranded cDNA molecule was generated using DNA Polymerase I and DNA Ligase. The cDNA was then purified and concentrated using a phenol:chloroform extraction followed by ethanol precipitation.
      </Extract-Protocol>
      <Label>Biotin</Label>
      <Label-Protocol>
The cDNA products were incubated with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro Transcription kit (Affymetrix). The resultant cRNA product was purified using an RNeasy column (Qiagen) and quantified with a spectrophotometer. The cRNA target (20ug) was incubated at 94ºC for 35 minutes in fragmentation buffer (Tris, MgOAc, KOAc).  The fragmented cRNA was diluted in hybridization buffer (MES, NaCl, EDTA, Tween 20, Herring Sperm DNA, Acetylated BSA) containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls (Affymetrix).
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Target was prepared and hybridized according to the &quot;Affymetrix Technical Manual&quot;. The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 45°C for 5 minutes and then injected into a GeneChip cartridge. The GeneChip array was incubated at 42°C for at least 16 hours in a rotating oven at 60 rpm.  GeneChips were washed with a series of nonstringent (25°C) and stringent (50°C) solutions containing variable amounts of MES, Tween20 and SSPE. The microarrays were then stained with Streptavidin Phycoerythrin and the fluorescent signal was amplified using a biotinylated antibody solution.
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images were detected in an GeneChip® Scanner 3000 and expression data was extracted using the GeneChip Operating System v 1.1 (Affymetrix).  All GeneChips were scaled to a median intensity setting of 500.
    </Scan-Protocol>
    <Description>
Enrollment protocol: Subjects were enrolled at Duke University Medical Center (DUMC; Durham, NC) as part of a prospective, NIH-sponsored study to develop novel diagnostic tests for severe sepsis and community-acquired pneumonia (ClinicalTrials.gov NCT00258869).  Enrolled patients had a known or suspected infection a exhibited two or more Systemic Inflammatory Response Syndrome criteria. Patients were excluded if they had an imminently terminal co-morbid condition, advanced AIDS (CD4 count &lt; 50), were receiving antibiotics prior to enrollment, or were enrolled in another clinical trial. Subjects in the current report had culture-confirmed monomicrobial BSI due to S. aureus (n=26; median age 55 years; range 40-91) or E. coli (n=14; median age 51.5 years; range 25-91). Uninfected controls (n=44; median age 26 years; range 20-59) were enrolled at DUMC as part of study investigating the effect of aspirin on platelet function among healthy.
    </Description>
    <Data-Processing>
Data processing was conducted using the Robust Multichip Average (RMA) generated by Affymetrix Expression Console software.   Microarray data was analyzed in two steps following the analysis strategy.  First, a Bayesian sparse factor model was fit to the expression data without regard to phenotype. Second, factors were then used as independent variables to build a penalized binary regression with variable selection model trained to identify S. aureus infection. In order to minimize issues with overfitting, batch was not included in the regression models. This approach also allows for model averaging, which properly accounts for uncertainty in the choice of predictors and typically outperforms the single best model in predictive accuracy. Genes were filtered for analysis using non-specific filtering for genes with high mean expression and high variance across samples. Samples with a high number of outlying genes were removed during the factor analysis. Mice were batched into discrete experiments with each experiment containing the relevant controls to avoid confounding. Using the same murine experimental data, another classifier was derived to classify methicillin-resistant vs. methicillin-sensitive S. aureus infection. The methodology was otherwise the same as that described above.  We fit a factor model on the human data independently from the mouse data. The factor model was fit to 8,892 genes after non-specific filtering to remove unexpressed and uniformly expressed genes. The factor model was trained on the 95 samples from three batches of expression data, and this resulted in 77 factors. These 77 factors were then projected onto the full data set with the goal of distinguishing S. aureus BSI from healthy controls or E. coli BSI. Leave-one-out cross-validation was utilized in order to control for overfitting of the penalized binary regression model. In order to minimize issues with overfitting, batch was not included in the regression models. Matlab scripts to perform these operations are available.
    </Data-Processing>
    <Platform-Ref ref="GPL571" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="CEL">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932384/suppl/GSM932384_2739_136864_HG-U133A_2_DU10-01S06732_N2.CEL.gz
    </Supplementary-Data>
    <Supplementary-Data type="CHP">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM932nnn/GSM932384/suppl/GSM932384_2739_136864_HG-U133A_2_DU10-01S06732_N2.rma.chp.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>The RMA output is data in log2 form. Probeset value as output by Affymetrix Expression Console software.</Description>
      </Column>
    <External-Data rows="22277">
GSM932384-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Series iid="GSE33341">
    <Status database="GEO">
      <Submission-Date>2011-10-31</Submission-Date>
      <Release-Date>2013-01-11</Release-Date>
      <Last-Update-Date>2019-02-11</Last-Update-Date>
    </Status>
    <Title>Gene Expression-Based Classifiers Identify Staphylococcus aureus Infection in Mice and Humans</Title>
    <Accession database="GEO">GSE33341</Accession>
    <Pubmed-ID>23326304</Pubmed-ID>
    <Summary>
Staphylococcus aureus causes a spectrum of human infection. Diagnostic delays and uncertainty lead to treatment delays and inappropriate antibiotic use. A growing literature suggests the host’s inflammatory response to the pathogen represents a potential tool to improve upon current diagnostics. The hypothesis of this study is that the host responds differently to S. aureus than to E. coli infection in a quantifiable way, providing a new diagnostic avenue. This study uses Bayesian sparse factor modeling and penalized binary regression to define peripheral blood gene-expression classifiers of murine and human S. aureus infection. The murine-derived classifier distinguished S. aureus infection from healthy controls and Escherichia coli-infected mice across a range of conditions (mouse and bacterial strain, time post infection) and was validated in outbred mice (AUC&gt;0.97). A S. aureus classifier derived from a cohort of 95 human subjects distinguished S. aureus blood stream infection (BSI) from healthy subjects (AUC 0.99) and E. coli BSI (AUC 0.82). Murine and human responses to S. aureus infection share common biological pathways, allowing the murine model to classify S. aureus BSI in humans (AUC 0.84). Both murine and human S. aureus classifiers were validated in an independent human cohort (AUC 0.95 and 0.94, respectively).  The approach described here lends insight into the conserved and disparate pathways utilized by mice and humans in response to these infections.  Furthermore, this study advances our understanding of S. aureus infection; the host response to it; and identifies new diagnostic and therapeutic avenues.
    </Summary>
    <Overall-Design>
To create a host gene expression-based classifier for S. aureus infection, mice from a variety of experimental conditions were utilized.  Seven different strains of inbred mice (n=187 total) were challenged with four different S. aureus strains via intraperitoneal inoculation and sacrificed at various time points as described in Methods.  The comparator group for model derivation included 50 A/J or C57BL/6J mice inoculated with E. coli (O18:K1:H7) as well as 54 uninfected mice. Next, the murine S. aureus classifier was externally validated in outbred CD-1 mice with S. aureus infection (Sanger 476 or USA300), E. coli infection (O18:K1:H7), or uninfected controls (10 animals per condition).   Method: All experiments were performed on mice 6-8 weeks old.  For the murine S. aureus predictor, seven inbred mouse strains (3 mice/strain: 129S1/SvImJ, A/J, AKR/J, BALB/cByJ, C57BL/6J, C3H/HeJ, and NOD/LtJ) were IP inoculated with 107 CFU/g of S. aureus Sanger476, euthanized at 2h after injection, and bled. This was repeated using four different S. aureus strains (USA100, USA300, MW2, and Sanger476) in A/J mice (n=3 per S. aureus strain). For time series experiments, both A/J and C57BL/6J mouse strains were IP inoculated with S. aureus Sanger476 as above, and sacrificed at 2, 4, 6, and 12h after injection (n=5 per time point).
    </Overall-Design>
    <Type>Expression profiling by array</Type>
    <Contributor-Ref ref="contrib3" position="1" />
    <Contributor-Ref ref="contrib4" position="2" />
    <Contributor-Ref ref="contrib5" position="3" />
    <Contributor-Ref ref="contrib6" position="4" />
    <Contributor-Ref ref="contrib7" position="5" />
    <Contributor-Ref ref="contrib8" position="6" />
    <Contributor-Ref ref="contrib9" position="7" />
    <Contributor-Ref ref="contrib10" position="8" />
    <Contributor-Ref ref="contrib11" position="9" />
    <Contributor-Ref ref="contrib12" position="10" />
    <Contributor-Ref ref="contrib13" position="11" />
    <Contributor-Ref ref="contrib14" position="12" />
    <Contributor-Ref ref="contrib15" position="13" />
    <Contributor-Ref ref="contrib16" position="14" />
    <Contributor-Ref ref="contrib17" position="15" />
    <Contributor-Ref ref="contrib18" position="16" />
    <Contributor-Ref ref="contrib19" position="17" />
    <Contact-Ref ref="contrib1" />
    <Sample-Ref ref="GSM824455" />
    <Sample-Ref ref="GSM824456" />
    <Sample-Ref ref="GSM824457" />
    <Sample-Ref ref="GSM824458" />
    <Sample-Ref ref="GSM824459" />
    <Sample-Ref ref="GSM824460" />
    <Sample-Ref ref="GSM824461" />
    <Sample-Ref ref="GSM824462" />
    <Sample-Ref ref="GSM824463" />
    <Sample-Ref ref="GSM824464" />
    <Sample-Ref ref="GSM824465" />
    <Sample-Ref ref="GSM824466" />
    <Sample-Ref ref="GSM824467" />
    <Sample-Ref ref="GSM824468" />
    <Sample-Ref ref="GSM824469" />
    <Sample-Ref ref="GSM824470" />
    <Sample-Ref ref="GSM824471" />
    <Sample-Ref ref="GSM824472" />
    <Sample-Ref ref="GSM824473" />
    <Sample-Ref ref="GSM824474" />
    <Sample-Ref ref="GSM824475" />
    <Sample-Ref ref="GSM824476" />
    <Sample-Ref ref="GSM824477" />
    <Sample-Ref ref="GSM824478" />
    <Sample-Ref ref="GSM824479" />
    <Sample-Ref ref="GSM824480" />
    <Sample-Ref ref="GSM824481" />
    <Sample-Ref ref="GSM824482" />
    <Sample-Ref ref="GSM824483" />
    <Sample-Ref ref="GSM824484" />
    <Sample-Ref ref="GSM824485" />
    <Sample-Ref ref="GSM824486" />
    <Sample-Ref ref="GSM824487" />
    <Sample-Ref ref="GSM824488" />
    <Sample-Ref ref="GSM824489" />
    <Sample-Ref ref="GSM824490" />
    <Sample-Ref ref="GSM824491" />
    <Sample-Ref ref="GSM824492" />
    <Sample-Ref ref="GSM824493" />
    <Sample-Ref ref="GSM824494" />
    <Sample-Ref ref="GSM824495" />
    <Sample-Ref ref="GSM824496" />
    <Sample-Ref ref="GSM824497" />
    <Sample-Ref ref="GSM824498" />
    <Sample-Ref ref="GSM824499" />
    <Sample-Ref ref="GSM824500" />
    <Sample-Ref ref="GSM824501" />
    <Sample-Ref ref="GSM824502" />
    <Sample-Ref ref="GSM824503" />
    <Sample-Ref ref="GSM824504" />
    <Sample-Ref ref="GSM824505" />
    <Sample-Ref ref="GSM824506" />
    <Sample-Ref ref="GSM824507" />
    <Sample-Ref ref="GSM824508" />
    <Sample-Ref ref="GSM824509" />
    <Sample-Ref ref="GSM824510" />
    <Sample-Ref ref="GSM824511" />
    <Sample-Ref ref="GSM824512" />
    <Sample-Ref ref="GSM824513" />
    <Sample-Ref ref="GSM824514" />
    <Sample-Ref ref="GSM824515" />
    <Sample-Ref ref="GSM824516" />
    <Sample-Ref ref="GSM824517" />
    <Sample-Ref ref="GSM824518" />
    <Sample-Ref ref="GSM824519" />
    <Sample-Ref ref="GSM824520" />
    <Sample-Ref ref="GSM824521" />
    <Sample-Ref ref="GSM824522" />
    <Sample-Ref ref="GSM824523" />
    <Sample-Ref ref="GSM824524" />
    <Sample-Ref ref="GSM824525" />
    <Sample-Ref ref="GSM824526" />
    <Sample-Ref ref="GSM824527" />
    <Sample-Ref ref="GSM824528" />
    <Sample-Ref ref="GSM824529" />
    <Sample-Ref ref="GSM824530" />
    <Sample-Ref ref="GSM824531" />
    <Sample-Ref ref="GSM824532" />
    <Sample-Ref ref="GSM824533" />
    <Sample-Ref ref="GSM824534" />
    <Sample-Ref ref="GSM824535" />
    <Sample-Ref ref="GSM824536" />
    <Sample-Ref ref="GSM824537" />
    <Sample-Ref ref="GSM824538" />
    <Sample-Ref ref="GSM824539" />
    <Sample-Ref ref="GSM824540" />
    <Sample-Ref ref="GSM824541" />
    <Sample-Ref ref="GSM824542" />
    <Sample-Ref ref="GSM824543" />
    <Sample-Ref ref="GSM824544" />
    <Sample-Ref ref="GSM824545" />
    <Sample-Ref ref="GSM824546" />
    <Sample-Ref ref="GSM824547" />
    <Sample-Ref ref="GSM824548" />
    <Sample-Ref ref="GSM824549" />
    <Sample-Ref ref="GSM824550" />
    <Sample-Ref ref="GSM824551" />
    <Sample-Ref ref="GSM824552" />
    <Sample-Ref ref="GSM824553" />
    <Sample-Ref ref="GSM824554" />
    <Sample-Ref ref="GSM824555" />
    <Sample-Ref ref="GSM824556" />
    <Sample-Ref ref="GSM824557" />
    <Sample-Ref ref="GSM824558" />
    <Sample-Ref ref="GSM824559" />
    <Sample-Ref ref="GSM824560" />
    <Sample-Ref ref="GSM824561" />
    <Sample-Ref ref="GSM824562" />
    <Sample-Ref ref="GSM824563" />
    <Sample-Ref ref="GSM824564" />
    <Sample-Ref ref="GSM824565" />
    <Sample-Ref ref="GSM824566" />
    <Sample-Ref ref="GSM824567" />
    <Sample-Ref ref="GSM824568" />
    <Sample-Ref ref="GSM824569" />
    <Sample-Ref ref="GSM824570" />
    <Sample-Ref ref="GSM824571" />
    <Sample-Ref ref="GSM824572" />
    <Sample-Ref ref="GSM824573" />
    <Sample-Ref ref="GSM824574" />
    <Sample-Ref ref="GSM824575" />
    <Sample-Ref ref="GSM824576" />
    <Sample-Ref ref="GSM824577" />
    <Sample-Ref ref="GSM824578" />
    <Sample-Ref ref="GSM824579" />
    <Sample-Ref ref="GSM824580" />
    <Sample-Ref ref="GSM824581" />
    <Sample-Ref ref="GSM824582" />
    <Sample-Ref ref="GSM824583" />
    <Sample-Ref ref="GSM824584" />
    <Sample-Ref ref="GSM824585" />
    <Sample-Ref ref="GSM824586" />
    <Sample-Ref ref="GSM824587" />
    <Sample-Ref ref="GSM824588" />
    <Sample-Ref ref="GSM824589" />
    <Sample-Ref ref="GSM824590" />
    <Sample-Ref ref="GSM824591" />
    <Sample-Ref ref="GSM824592" />
    <Sample-Ref ref="GSM824593" />
    <Sample-Ref ref="GSM824594" />
    <Sample-Ref ref="GSM824595" />
    <Sample-Ref ref="GSM824596" />
    <Sample-Ref ref="GSM824597" />
    <Sample-Ref ref="GSM824598" />
    <Sample-Ref ref="GSM824599" />
    <Sample-Ref ref="GSM824600" />
    <Sample-Ref ref="GSM824601" />
    <Sample-Ref ref="GSM824602" />
    <Sample-Ref ref="GSM824603" />
    <Sample-Ref ref="GSM824604" />
    <Sample-Ref ref="GSM824605" />
    <Sample-Ref ref="GSM824606" />
    <Sample-Ref ref="GSM824607" />
    <Sample-Ref ref="GSM824608" />
    <Sample-Ref ref="GSM824609" />
    <Sample-Ref ref="GSM824610" />
    <Sample-Ref ref="GSM824611" />
    <Sample-Ref ref="GSM824612" />
    <Sample-Ref ref="GSM824613" />
    <Sample-Ref ref="GSM824614" />
    <Sample-Ref ref="GSM824615" />
    <Sample-Ref ref="GSM824616" />
    <Sample-Ref ref="GSM824617" />
    <Sample-Ref ref="GSM824618" />
    <Sample-Ref ref="GSM824619" />
    <Sample-Ref ref="GSM824620" />
    <Sample-Ref ref="GSM824621" />
    <Sample-Ref ref="GSM824622" />
    <Sample-Ref ref="GSM824623" />
    <Sample-Ref ref="GSM824624" />
    <Sample-Ref ref="GSM824625" />
    <Sample-Ref ref="GSM824626" />
    <Sample-Ref ref="GSM824627" />
    <Sample-Ref ref="GSM824628" />
    <Sample-Ref ref="GSM824629" />
    <Sample-Ref ref="GSM824630" />
    <Sample-Ref ref="GSM824631" />
    <Sample-Ref ref="GSM824632" />
    <Sample-Ref ref="GSM824633" />
    <Sample-Ref ref="GSM824634" />
    <Sample-Ref ref="GSM824635" />
    <Sample-Ref ref="GSM824636" />
    <Sample-Ref ref="GSM824637" />
    <Sample-Ref ref="GSM824638" />
    <Sample-Ref ref="GSM824639" />
    <Sample-Ref ref="GSM824640" />
    <Sample-Ref ref="GSM824641" />
    <Sample-Ref ref="GSM824642" />
    <Sample-Ref ref="GSM824643" />
    <Sample-Ref ref="GSM824644" />
    <Sample-Ref ref="GSM824645" />
    <Sample-Ref ref="GSM824646" />
    <Sample-Ref ref="GSM824647" />
    <Sample-Ref ref="GSM824648" />
    <Sample-Ref ref="GSM824649" />
    <Sample-Ref ref="GSM824650" />
    <Sample-Ref ref="GSM824651" />
    <Sample-Ref ref="GSM824652" />
    <Sample-Ref ref="GSM824653" />
    <Sample-Ref ref="GSM824654" />
    <Sample-Ref ref="GSM824655" />
    <Sample-Ref ref="GSM824656" />
    <Sample-Ref ref="GSM824657" />
    <Sample-Ref ref="GSM824658" />
    <Sample-Ref ref="GSM824659" />
    <Sample-Ref ref="GSM824660" />
    <Sample-Ref ref="GSM824661" />
    <Sample-Ref ref="GSM824662" />
    <Sample-Ref ref="GSM824663" />
    <Sample-Ref ref="GSM824664" />
    <Sample-Ref ref="GSM824665" />
    <Sample-Ref ref="GSM824666" />
    <Sample-Ref ref="GSM824667" />
    <Sample-Ref ref="GSM824668" />
    <Sample-Ref ref="GSM824669" />
    <Sample-Ref ref="GSM824670" />
    <Sample-Ref ref="GSM824671" />
    <Sample-Ref ref="GSM824672" />
    <Sample-Ref ref="GSM824673" />
    <Sample-Ref ref="GSM824674" />
    <Sample-Ref ref="GSM824675" />
    <Sample-Ref ref="GSM824676" />
    <Sample-Ref ref="GSM824677" />
    <Sample-Ref ref="GSM824678" />
    <Sample-Ref ref="GSM824679" />
    <Sample-Ref ref="GSM824680" />
    <Sample-Ref ref="GSM824681" />
    <Sample-Ref ref="GSM824707" />
    <Sample-Ref ref="GSM824708" />
    <Sample-Ref ref="GSM824709" />
    <Sample-Ref ref="GSM824710" />
    <Sample-Ref ref="GSM824711" />
    <Sample-Ref ref="GSM824712" />
    <Sample-Ref ref="GSM824713" />
    <Sample-Ref ref="GSM824714" />
    <Sample-Ref ref="GSM824715" />
    <Sample-Ref ref="GSM824716" />
    <Sample-Ref ref="GSM824717" />
    <Sample-Ref ref="GSM824718" />
    <Sample-Ref ref="GSM824719" />
    <Sample-Ref ref="GSM824720" />
    <Sample-Ref ref="GSM824721" />
    <Sample-Ref ref="GSM824722" />
    <Sample-Ref ref="GSM824723" />
    <Sample-Ref ref="GSM824724" />
    <Sample-Ref ref="GSM824725" />
    <Sample-Ref ref="GSM824726" />
    <Sample-Ref ref="GSM824727" />
    <Sample-Ref ref="GSM824728" />
    <Sample-Ref ref="GSM824729" />
    <Sample-Ref ref="GSM824730" />
    <Sample-Ref ref="GSM824731" />
    <Sample-Ref ref="GSM824732" />
    <Sample-Ref ref="GSM824733" />
    <Sample-Ref ref="GSM824734" />
    <Sample-Ref ref="GSM824735" />
    <Sample-Ref ref="GSM824736" />
    <Sample-Ref ref="GSM824737" />
    <Sample-Ref ref="GSM824738" />
    <Sample-Ref ref="GSM824739" />
    <Sample-Ref ref="GSM824740" />
    <Sample-Ref ref="GSM824741" />
    <Sample-Ref ref="GSM824742" />
    <Sample-Ref ref="GSM824743" />
    <Sample-Ref ref="GSM824744" />
    <Sample-Ref ref="GSM824745" />
    <Sample-Ref ref="GSM824746" />
    <Sample-Ref ref="GSM824747" />
    <Sample-Ref ref="GSM824748" />
    <Sample-Ref ref="GSM824749" />
    <Sample-Ref ref="GSM824750" />
    <Sample-Ref ref="GSM824751" />
    <Sample-Ref ref="GSM824752" />
    <Sample-Ref ref="GSM824753" />
    <Sample-Ref ref="GSM824754" />
    <Sample-Ref ref="GSM824755" />
    <Sample-Ref ref="GSM824756" />
    <Sample-Ref ref="GSM824757" />
    <Sample-Ref ref="GSM824758" />
    <Sample-Ref ref="GSM824759" />
    <Sample-Ref ref="GSM824760" />
    <Sample-Ref ref="GSM824761" />
    <Sample-Ref ref="GSM824762" />
    <Sample-Ref ref="GSM824763" />
    <Sample-Ref ref="GSM824764" />
    <Sample-Ref ref="GSM824765" />
    <Sample-Ref ref="GSM824766" />
    <Sample-Ref ref="GSM824767" />
    <Sample-Ref ref="GSM824768" />
    <Sample-Ref ref="GSM824769" />
    <Sample-Ref ref="GSM824770" />
    <Sample-Ref ref="GSM824771" />
    <Sample-Ref ref="GSM824772" />
    <Sample-Ref ref="GSM824773" />
    <Sample-Ref ref="GSM824774" />
    <Sample-Ref ref="GSM824775" />
    <Sample-Ref ref="GSM824776" />
    <Sample-Ref ref="GSM824777" />
    <Sample-Ref ref="GSM824778" />
    <Sample-Ref ref="GSM824779" />
    <Sample-Ref ref="GSM824780" />
    <Sample-Ref ref="GSM824781" />
    <Sample-Ref ref="GSM824782" />
    <Sample-Ref ref="GSM824783" />
    <Sample-Ref ref="GSM824784" />
    <Sample-Ref ref="GSM824785" />
    <Sample-Ref ref="GSM824786" />
    <Sample-Ref ref="GSM824787" />
    <Sample-Ref ref="GSM824788" />
    <Sample-Ref ref="GSM824790" />
    <Sample-Ref ref="GSM932374" />
    <Sample-Ref ref="GSM932375" />
    <Sample-Ref ref="GSM932376" />
    <Sample-Ref ref="GSM932377" />
    <Sample-Ref ref="GSM932378" />
    <Sample-Ref ref="GSM932379" />
    <Sample-Ref ref="GSM932380" />
    <Sample-Ref ref="GSM932381" />
    <Sample-Ref ref="GSM932382" />
    <Sample-Ref ref="GSM932383" />
    <Sample-Ref ref="GSM932384" />
    <Supplementary-Data type="TAR">
ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE33nnn/GSE33341/suppl/GSE33341_RAW.tar
    </Supplementary-Data>
    <Relation type="BioProject" target="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA148969" />
  </Series>

</MINiML>
